var title_f1_4_1088="Fistula tract";
var content_f1_4_1088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/78768/fistula_tract_conv.mp4?title=Fistula+tract\" style=\"width:354px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fistula tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Air within the fistula tract (arrow) seen during endorectal ultrasonography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1088=[""].join("\n");
var outline_f1_4_1088=null;
var title_f1_4_1089="Anterior uveitis in a patient with IBD";
var content_f1_4_1089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75384%7EGAST%2F70384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75384%7EGAST%2F70384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior uveitis in a patient with inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 177px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior uveitis in a patient with inflammatory bowel disease is characterized by injection of the conjunctiva and opacity in the anterior chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 181px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC1AOwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VPWiipYIjI6joD3pDjFydkJFGXYDsa2dP0xmUSZUYHfvXRt4RGmaTpuoy3tlcLfxuwghfdJDtOPnGOM9qtaVpc1xIiRR/Ke5HWuSpiY20Z9dlWRuVp1Ff/gGdY2Z4AAyOua3PsqQpCj4QE/MxroLrw0YIonmzGyH94pGCT6EVUtNHvfEuuLpOmIm/HmM7nCouPvE+lef9YVV+69D7KlChg6MqjasuvQ5a9kUSOQx2g/Ln0qHTLy2j1GOa9t5Lm3Q7jCrbfMx2J7CvRPH3h7SfDukWmg2US3uvysJ7q8yf3ac4RV/hB4PPOMetcGLER5AdHIOPl9fauiM4tWPKhKpjbVqS917Pv6eXYs+IPEGq6/IFu7h4rBMCGxiYiGFRwAq9Px6mqp0qeC1jnlt2jhkPyO4xv8Ap6j3q3Bpt6JN8aMhBxvzjFTatp89okU11MZy5wTkt+pqVVimoxaOingPZxcnH9ClParDGjCaJ2b+Fc5H14plvC00yRoMuxwBXZSXunz6fiKOLeRjaq7m/KqVhZtpkscsaPc7/lcKhBT0NYrFPlfMrM73hE5JrYmn8MwxW6yNIc4+YDPBrHm0qRIS0ieWg4DEHn616jocdre27zu8S+WdrxzHBBHbHrWH4wjF4UtgsdooJIIOQwH9K4aWMnz8smOFSE6jpcmq36HmwjY/dUnnHFSiNvLDFDtPQ16DoPhC7Fo959lbbjKmRtpcf7K1q23g5r7ToJ4SEjm5YgjIHb9f510TzGEX5GDeGpX56i7fM8lljKMQwIb0NM8rIztyB1OK7HxB4c8i7e3aZmmQAbmH6mtrStCXUN1r5cKsgyWY4z+FaPHwUFJFyw9OzqOXu9GeXvArD5SQfaojFKn3H6etena18PrhIxJGgViP+WZyPxFcC1lLHcmGVWUhtpIrehi6dZe6zhlh41NaTuu6Zni5kjHzJnscVKlzFIMA4Poa330CTaPuSccfwn6Vnz6D7+VJ/dYf1q1XpPqW8JiofDr5GYyBmyvNKlurszFtiqCScAn2wKe+k31vKqyRybGO0MOhPpmt3S/E8Gm+GLrR5tEsp7iaVmlurlNzIpUAKvGVYHJyD3wRVud1eGpwyTj/ABIW1MuGbw7NZpHfWeo2t2G5nt5VkTGOuxgDnP8AtVzV9HEk7iGXzowflfaVz+HarM0iq+0nI9agkUMMgg1rCPK73PJxNql1pf8Ar5fgUX5UEknHTNV5DxVuRD2qrKNtdEWeHiItIrGgUrcnIpKs8trURVLNhRk1u6VpsswDIobA5qnplr5kyljx616PoFrhQkaK4PKkVyYmv7NaH1OQZSsQ3VqbIh0mzkknRWCIY/lZMZJrvdIiWwdJZU3IoyoTggisrTtLaW7MkQMewcMK09b1n+z7Dy5cfKMfKo6+x9a8OtUdSSUT7irFWVKOq6+hS8beKWdXh3mR2bcwPPPqT3pnw18RXelaZqsVnAn2i5K7bl1GIgOp6ZJ9B0HWuYsdMuNcu5Lpz5cHLZb0FdJ4cAt7xJZdNl1DTrc4NuvyBzjgu3cZ5xWrUaUOSL97qYywtOpRcJQvTW0e/Vb2Wtuv5Foabd3dnJfzwyiCXcfts/8Ay1Y989TzVa2tNE0i0kN3MrXuAocjO38KreOdV1K+2C5mNvbg7YrKMELGvoPpUfhTS7e+jT7RGiyHJ3P3H41k42p87enZG8ZTcbVfdtrp0XT/AIO33DL/AMSwpEEtYpJBxhnG1WArET7Trd6UMmM/MFzwPpXbaxpCQRwlFiljj3MRj0/pzTrXweXitrmzmjtrgnzAHQkHjpkUQxNGnG6Vn3Cc4cqlKfuvoZ/hfwhdSXySSSt5Sn5ljByx9MZr1ODRYGhj3Rkqg4Vucn3FUfCmqwLPJY6iqWuoIQuH+7MMfeUnp9K68AMmQT6g81x1PaYmV5PU+QznNa+HqezUeWK28/8AM5/UNC0wtAr2kYkkJ3mNfmYY7+3vXJS2NtFqE1rKFW0ChBOVzs7jOOpr05goGNuQeOBzzXIPDu8YQGWJZ1diAGHytheuPUVm6cqU7N7lZNm060JqUn7qb3+eh0sMTRQRWpPnGOPKsx5IzgZ+lRaNa/Y4ZLcMcq24jGQc9x7e1XXP7yMshKDv6e/0p77mxsYA9uM/hVRgnLmfQ+enip8jp/za/O/9feYXinSxqNqGIRVgO6TcNpZQOgbBxVmx06CO0t5beGOJii53LnjHAP0qrp99b6jr8ywqjxwQFJNwwQxbjjoT159K6Bjn6d896UaPOnf5HXi8ZXwlOnhp301fz6fqQLEGTK8BlB2n6V5H470WUaiknleXb79xkjGWGOx9K9hbJB5wc4xVS/iSQqGXfgYIxnNJP2NpxNsnzR4au+ZXTPLNKlt7q0SNgvnfdVz91/8ACtW48MJcXHlRqXcoWQADAC9c59Ki1rw09jMsthIqwOxZ4wuSPb9avRahe6WFeeMTCQhAjMVkSnKevNBn2VSvKrFVMJLe+j7ml4LtdQsLGeG0NtqEBYvJp8jbZAT/ABJkYOR2rB1fSvBfiXUZ01S1uvD2orwQ4EaN74xgH8q6G+jhutOsmmgure5dN0cwXjOT1zg/zrKivLuO2nS/S016xXckkNwS7LjqEc/MprenX7vX+u2p4X1d4idSutJN9HZ/jeEvmk+7PHfiN4WsPDd1bjS9ZttUgnBJWM/PERj72MjBz69jXFjgYHHv611GtW1s93ObWN4Ii5KxStllHpnvWh4Cu9B03UZ4/Fmk/wBpafcR+UHViHtzn7688/SvoKU2qab1ZlisDOk9bu3pf9DiB83r+NMmiyte0eIfhALixk1XwRqUOp2O0uICfn9cKRwT7HB9q8ZuC8UrJIpRgcFSOQa0pVVU23PMk6couzv09PVPVfMzpYjnioSMdavsyt9aa0YJJrpTPKqYZN3izstJ01Sq7kAPBIx2zXpnhzw+btUaIosYGc+tZOk2fnywpGADjBzXoukyro+kq9zj5MqRjkHrjPevnq9bneux+gY2tLA0FSwy996Izde8nRtOKttEm3Bfp2rypRNr+rOxLmEHJ+n/ANet7xTqk/ijV2tLcMtvETuIOelN0/U7XQw8Aj8yeNvuFc5PYUqUXSTaV5P8EdeDoThRSqavd+b7eiNSFobWzNnbLvlkX/VBeg9WPYVteG5ILHRYoWmRZGBdpO45/WuNS7mjF1NLC2ZcylVb7oPb8K6Hw3Yrf7JgyBWjBIY1zVYWjqdeMowdJ+0dluZ3iyP+1bmKOONiruESXbj3J/IGrdpYpYu8kMLx+UikMUyD9a3dJfOvWdvGySfZnklcOu4KACoz9SeK6u6gaOxkjFukpnIXLcDBGOeMj6VlOq1FR6HmYnMo4acaPLul16X/AMhha3l0zfaos8jwlRsXJOcZHPFW5U3W1rHawqhG1lRvlOB2OKWxWO1WO1Qgl1AIxjawAGSP881pIm0BQWLY+8eprCNJzvy7Hx+Jx0aLWj3bV+pydxpsWpeJZbXWLfdCYBJbKHJAIPzHPHPIrqrSPyYI7fL4jXCu3dR0yfWqerwtNPppg/dzC5UBx1CkHcPoQMf/AKq0XbaDnOzPHGa6KEHBtt6I5szxrxVGkujW3ZrS69RlxKIoWkZwiqCSx7CseLzr6906/S3MEKK5VpWALqy8YA/rVq/nlS5itBBG7XWQjNkqqgfMW9e3Hv1qzZWi2tnb229pBbgAMw5/+tTalWbl2IpShgKKb+KV/wDwFppv79NSwD+7ByGTGeO9I2WVlX5SASGFNhiWNdvJGSenXJpH43Kq5z/eNVL4btbnBFrntF9TiJdPubDUHvrBPOlmLGSJQRkZ/Q812dvc7okEgCkqG9PwNYmsawlo++RWMluw3AHgqRng9sjH5VzGt+NLYfLBKYSGbHI5rnipt+4fX16NXMYQ9rGyXX8j0dplGASQTz71C84A3yFEUDPXgjr+dfPmsfEebmOKWUhCdoBGFrJk+I05Xb5TAcHAfAyO9dscBXnrY4Xl+Eo6SrK/ofSs6Q+ZibZnsGORz35rFvdOGorGYnCmGYglvm3be2fSvCU+J93lTIszbQcAycZ9asaT8Tp7a42IrLHI/JLfdB60Sy2tukb4V06OsK65ul0z3nTI5fIltbtX2xuSp3Z3Ke5/UfhUV3pYiuDd2pQR4CyJ2b0OfWuA034rWs1wVZEWMnyyWPzYHcH0rqbbXLTV4XUSlZi2IwpyO3U5rjq0J0/iVmb06WJVR1Ytcr3tqvPQ4bx7ZWTXsN6m3awHnrt2kc+nqK5CTR5HspJwu2RXddg/2WI/UAH8a9w1+whuLSaKVUdwhw2PmVu31rzwwXWj2sOnzsZbeZi6hjnBIxke3H6V2YbEyjHlW6/I+iwVSGLppfn+fyOBtNS1HS5Fm0y+uLOQHOYZCnI9cVasbyDxT4khj8XTSs15OqvfxgeYmQFGR0I6frT9Y037JK3lqzREZbjlP/rViTxBO+c8g17EXGoro8zGYSVOTf3/ANP+rnQ/Ez4X6j4MkSaGR77T2BzcLEVMbA/dcc4PvnmvP1JxyDX0/wDCLxDqV58Pb661V7a6stMaSNmnlKy7FQOASQVbrhQcZ6V5h8WLvwdq3ieK+0WU7J7VGnFvD5aiXLZ+U4wcbc44zThiJJ8klf8Ar+v8j5SFOfO4SW3VbP5dHb/gHd+F7c21wJrnY0BGXGORWJ418QNrF4dNsCyIOrbuFHf+VL4y8RGxhNnCCCDtIBwT6Z+lcamoC0tpCB/pEnLufU15dGlKXvteh93RownV+tVtHb7l/m/yNlHXTLLyLeQYb5nlxhvp+NZVncwjUhdXDiOKV9gJ5IH1/CsaW9knGGYtk+tWrS2ikuIkuJXWE4LsBnaa61R5U3J6s6lilUaVJbfn/wAMej3eqaXHpyoqmV+h2pnI9K46DUrtJZbO1lMETszRBxggH+HNdfovg7Ult4Z7XU4pYZQfLSTJAHPf14rn/FdjdWlvLHd2zFkfetxH9wgn0ripezUuRa3/AK6hSr0XeMJXau2r/ebHh6+1nQC+o3ULnT5HUSOAGKkcAEema9Gi8TWd0lukKM1zKRi3Ycg+vpisj4c6nputaALN49stvF/pKPjbIOBu/lTbfwtdQXVze6HLBGokxACucoev4D+lcldtNqWj8jwsVLB4ytNYqPJOD0b0Tvtd/wBaHexoqqGUA5LNnHXJz+FPP5A9sVR0OK/i0xY9WKNcq5GVOcjPFaGMMeR+ddFOKlBJKx+f4pOnXnHmUrPdbP0K1xJFFcRebIo27pAuMk8bcfXnP4VJOwWF5GISMDcXY4GOuazbqxS6nv1d2EsigDaTGF+U4PHXoR71b1CzS80+W2LeWZYivmAcjPf3rkjOU1KKW56U6WHg6TlN+emy3/VlHRYbiS/u9SnbdbzKEts9dmc5x2B4rZA49RUNkHis4YpFAaNFRtvQ4GMj2p0kqqVBPLdB3Nd9NRp01c8/HVp4rESa22Vuy2FZ1XapIGTjrye9cR4m8QHdKIZZIPs4ISQSYG7nkik8d+KrfSbMPKpP3gE6EnH6V86+KfEl3rlyxbMVvuO2JScfj60UcNLFSvtFHt4ClDAw9vVV5PZHR+JPHjyBoLd3mZePNJwPp7ivP7m9mnYmSRjznrULKc/NTGYdhXu0aEKStFHNjMfXxD992XYCxzz1pM008mitzzG2x2TQDSUUCuOV2U5BNaml63d6e+YJXUZyQDway32728sMEzwGOTTamUVJWaN6OJq0Jc1OVme1eEPiIskUlvdLJJJIQBukJz2OD610d3PBeaWs4l3kgoFI5TjrmvnWOR42BQkH2rrvDXiTZm2vd7RyEfNnJFeTictV+emfZZPnlKpNQxHuyfXo/wDI6O0srrVLgDeXBO3GMk56D3p/iXw3c6RqD2FxGUmCeYARjtyK7/w3o89tHY69LAj6ZvJMbNtaQLycfhn8q7TxPpKeJtJsNQsJVuvspIxMMeYhx8rH+8pHXvn3rlWJkpO2y6f1/Vj18ZmNGlXhTetOV05dpdF5bW17+TPli+Fzbx8tIsM3IGSFfHGffFZwc44YCvUviNHZT3U2nQvJDd2skgkjkiRV3KMcFSevPI64FeSzEiQgV6+Gqe1he1mfNZrT+rSU4u8X/TOnm1Rri6nu5mJkckqCc7c1n3N4zsOuPSsyWQ5PNMEhJz3q40ktjOtms5rkbNOCYl24PB4r0vw34Mv72GzuLS5VJpVyc8jkdD9BzXmmjRq9yplz5QILEdcV73pHieO1tbX7FbpJbwoArsMEcAHcB1H6nFcWNqOFlH5nqYD6zKg6lBXl0v8An9+hzWoeGfEmkT3DW109zDasu50JC5Iz06YqJPHt5PAYNTginUgAvjDcGvabK6+02KzLBO8bdSYwC2e+3k/hWV4j8Kab4k01EESW0n30lijCtn0I/pXmupTn8avbXs/+CYUM+tOMMZCzTtffXz6q77HlFvZXcFx/bGjmPbPctDFCrZKnAPXj8K9ct31axsoZdUt2vIti+Y1tId6HPJZGAJIPHXtXjvh6xSDxM+m6jcTW1vveMShfuuvQ4/AV9BWgzaxuzB3ddrMDkORxkfXFKrS9rNR30un5fqbcSYyOGp0243Tbvv8Ag/66XWpHDeCdnCCSJ4yVlWaM5Q9RnHAGMd+lTSudjxRzL5+zd8gBKj1xSSwwyj97Esinjkcgex6iq2k2jWVrLFJMJx5reW5OWVM8Kc+mPxqJe1T5JdT4tfVpwdWGjjbTTX5/oXgBnazdOevJ96OOT36YH86A2Scj2weKTp7iuinBRStsefUqOTd9xGOAPxrmvGHiO38OaX9qvFMhYlEUcZP9BXQTuqRmSVgiLyST0FfM/wAWfEMuta0Ylkb7PCxCJngCrhS9rUUT0ctw/tbzl8Mf6sYPiXXLnXruS4uHYKWJVS2foPyrC2Bc7uR2qVSUXJA9BVR2PJPSvYpwUVyx2PcrzWjluR3BB+7VZj2pZZDnAqOuhI8KvUU5aC0UlLTMBaKSlFIYUUUUAJVzSpLWHU7STUY5prJZVM8cLhHZM/MFJBAOO9U6KHqCdtT6E1D4ky+JHuINRii0OG2EQ03TXjYmeNuNxbGMgAHsOeKn/t6eG1vprMtBbzI+6CJ22LuXaeM+nrXzz58hZC0rkoMISSdoHQD0ru28eSXGmpBb2/2P9wsFysUrbbkj+NwTySe3TgV5OJwDcuaHXc+xyPNsPCl9WrRslt+u3X8fMxdUu3lkLO7GQDqa5x3LMTmp76482UkE471Vr06ceVHgZljHiar1LErZckdO1LChdhiiQZc4FXdPt2kkUIpOeKG7IKNGVWrY9Z+DHha11Itc6hbCSJAXO7jPYAfz/CvUYNMsdKtINMlsogwUhJQSvnE9vY89/Sm/DnRo9N8M2SzIUnaBSxLnkHkY9PwrqZAGVkK5VhjmvCxEHWTlfUvFZu6eI9jFv2cbKydtV10eut/X5KxbW6W8CRIm0INgAPOOnWpBz908fnUYR0URo5OP+Wj8/hUiLkAsd2OwJIzWHtGmowieNKPPepOe5xfibwaNb8Qvd294bScwpIHUZ5BKnP1AFbthBqelaNHaw28VzJApBcSgBxychcZBPcc8mtWWNmeNoBH5qsSd/GUIwRnt6/hTxIufkdcjqNwyPriskrtxcrNf1/SPWq5rXqYenTqRU6ato11WnS3Tv+hHaS+fawS8DzI1fA7ZHIqTaAxbAyfvY71AbfDOYD5THkAD5CfXb7+1SIWGfPMXX76kgZ9MHp+dbSqOyhJa9zyvZQk3Upy0fTr/AMEkBx3/AP10mQdwwc0oHy5Oc+tN5A5Naq7tc5Hbocj8R9YGm6N5asfNnbYAPTFfNd5bzT3c883BU5bn1r1L4t6iX1l1LFoovlGCeDivMzf/ALiQFiQ3UEZ5rpwcXZzXU+9wWEp0cLCnUfn95j3UuXPAUDoKz55yRgGrV2eOevWs09a9WCPCx1aXNa+4lLSUorQ8wKXj1pMUooAKKWikAlH40tFACUUUhpgFAJoooAKUUlLQBopCWbn8a7HwHYxXGu2sUpARmGSegrFtLYNKcnOc12ngy1jXUEkYLlEwS3C/j6+tediqtqbR9zl+AcffPogQoEWIhWRQOCMjjFOgZJmchshTtC5OMdQa5nwxrVudOjtA6rMCz72PGzP3snv04966iFlZEaPGGXcBntXmKSqzVvmfFY3B1cA506ie+j/X5kgXAGQMjp7U0Dknnpilc7Rkjnp0zUEc6NdmGM/vFTdIw6r0AH45zV1JQjK3U4KVKpOLa2W5Oybv9aylA+4Js5BGcZOefXGKUHACqoCjoOBTgcEAAY9KjOMgZ5OcDviolTjGze5Uas5+6tkAAUYxxyenUk5J/MmlIDZBHB59R+VGcD7pwKY5lBURgZbnf2FTLlitSqanJ6aEhOQCD15+tMlOFI9u1KudqqzAsnynjHHrim3DbYnYdQpPTNWpXhchwtUUfM+efiCTc3Fw5GSZSc56jJrz28Qx7FOV4yR0r0HxdO5kaBVHBJOOf0rzu4LT3LgnkV34K/JY/R8wUVFKO+iM68PyDnmqNXL0YOKp16Udj4vFv94wpRSUoqjmFpamtbd7iTZGOcZrsbD4ca3f2vn29rOVxnJjOKznVhD4nY0jTlJXRxFFW9S0+5065aC7iaORTggiqlUmmrohpxdmFFFJTEFIaWkpgJS0UUAFKKSlFAHaA4cKFDHGBXSaRcqkBt2jZXVMkKQOPc1jQWjrHcBnCSQnJU9z0rtPCXhWHVprSK7kMbShp5GTlgo7ficCvHryg1Zn6pSn9Wg61TRJX+S/U9J8L+GxZ2dnehmt76WA+a27edrYIAHYgY555rpUhihWGBYxsz8pY/N9c+vesuW5vNOso4LSwe7+zIqli2C4HAwO5x1rz/xNqmtjxDBN9ilnntv3jxw7mWMMOFJHQ9q4JwjtBa9b/wDBPjaOGxOcVpVK1VKOrWqv5aJ369drnqP255NVNnAiERR+bLMw3KpJwEwCPm79elSadZfZRckyvK09w0jM4A/Tt0rhvCmv6y1zbLqEPlRT/KgmBXnLHduPUgk9ab8TvGEOnac+kaXKTdyALJIv8CY6D1JoheUrvWXT+vTdmdbJcRCssFStyySba10W7fz6fIn8TfEe10u/uLW1gW5eBtm/fwT3xjtS+HfHdvrs6QXcJsiwIEiSn73/ANfpXh27cxJPJ5rf8NR+dfRBgAo4z79q2q4SKp+87s+roZHgXDkjCzS3V7+vb5bH0gU2/JgbgMUKMEAntXO+CHuJbefz2JjiVEQHp3rpGwT61dJc0Oa1j8xzHDPB4mWHcua3UZ6cUyZQyMuDgjGal9cUjdMUSjdWOSMrNM8L13Qp5L+7Ljy2Dnnb2rzS/wBLuIJ52VGdQTzjvX1JqVolwJFkAG4ZYlc15Hf6Vlp0YkgscD8axw2KlBuLP03B1IZlSV9GjxO+XDc1TrqvFmnvBLvdcAnqK5Yjk19BSmpxTR8lmWHlh67jISpreMSOATjPeoqkhBZwB1NWzgjuevfDfwWt7NHLuDRA5Ybea+j7SFLe1jjjUKigADFeZ/BvT0ttNjlkmVvPQEAcbSP4fevUzgDGP/rV5HM5NybMcfO81Dojxn9obw0t7o6azAknnWw2ybFypXsSe3pXzea+4PENzFa6JezTpHIqQO5ikYANgE4yeO1fFer3Fvd6lcT2VqLS2dspCHL7B9Tya6cHJ3lDp/WhdKTlTV+mhTpKWkruKCkpaSmAlFLSUALSim04dKAPoDxTpEGkeI3uiAIpumegz71J4O1iK21y5uAyiFIPLZ84B53cH8K7jxVoraxprQE7mA3KNvr2zXjr+HGtr4QXRlgBfb8427ffJr5qKjJNTdn0P0nLsVDMsH7KVm7Wkr/j8z2nT/EEmsrFFo1nOGfk3NxGVhjHcg/xewFbWm2rWf2kSTtcSXMgldxGI1yFC9MnriqPhieFNKtbITlmt4VQt95eAOA4G0nHYc4rXKrKjCRPlYFWVvT0P4GtKPLJp3uz88zSboTnQpQ5IX9W9bp3fTTZaEcsaSTKksfmRbWb5hkA8Ajn1FeffEjwQL2OXVNOLtcAKHhAz8oXGR+VejnsFUDAx6fhSjKnPp+lCpcrco79CMBnFbBVIzhqrWa7r9D5XaGRJNsiMrdwRXR+Hj9mmB8ssMc5r1LxL4Lt76aS9tsibcWMRUYJ74/wqjo3g2Vrr/Sv3cA+Y+ppVMS5rka1P0vCZ3l7w7r8/TVPdeR2vhq4jn0S08sbdiBSnof881omqlhbRWVottAMIDnnvVkYyDjGK1pyfIrn5RjpU6mInOns22rinmj2pBw2RjFISSBmmzlKd7F5nHOPrXD63Z+TdvHyUmO8HHQ16E67hkYBxisPWrJruIbQBJGRjjqOeK8+tT5Zcy6n02R5l7CXJJ6HjPjrThJZMgAJxuHPQ/4149cxlHORjmvpXUNBe4tJAyDPJwRya8T8UeH57S5l+RyCxx8vNepl2IVuRs93N6SxsFVp6tHH1LC21geaSRGQkEEfWmV6+58hrF6no+gePJtPgjV23qnRGJxxXoFv8c1SzAuNOhklUY3LKV3fhg1885q7dXsU+nWVsljbQS24ffcR7t8+45G/JI+XoMAcdc1zPCwvddS5yjU+NXsd74z+LWteJtNn042llb2Mg+dUi3N9dxzj8K81qaC6uLeOeOCaSNJ08uVUYgOuQcH1GQD+FQ1tTpxpq0TPRaISlopKsANIaWkpiEooooGFKKSnUAfbUbbFAAIAHFVNc0yHVrH7PJlTncrY5FXIwJEzkBtoyAQSpxUkYYAqxPsc9frXzzp8ysyKWLnh6qq0naSKeiH7Faw2DR+WIk2RlBgMO/0P8608Zfnkn/IqF0RkILEZ7+lRLdpE4il4XGN5HB/GojUdL3J7dGVWh9dk61Ne891+v/ALoznnIz70MAwKgkZHDU1XVkBGCh6EHgindDwM+mK6E1a55zi07MO3OSaF4AwOntSjjjB47k5pQcDJqd3dhe2iE6tk8EcU7vycU0eu3PqaXAyOKa0E3cXjnGM+1KO/PFNH04xS4Hr1oAHHPemMozwOehp2T+tGDnjnNS1fcuLa2Kb26b8lODwRXMeJ/C0eoQs0ORLg9h6dK7AgkYB60xhlWBXrx64rldOzuj08LmNWhLmiz5Y8a+G7q1APkPlCc/IQcVxElvLHy8bgZxyK+z9W0q11KBo7iNSP72Oa8x8VfD8PbuY0dkDZXYufzr0aGO5EozR6XNQx7cr8sux8+26xNOi3DtHET8zKu4gewqOur1/wxLYuGjV2Vuc4xiudls5kJ3RuPqK9SFSM1dM46uFqU3ZorUU8xt6Gnw2000ipFE7uzBQAM5J6Cruc/LLsQ0ldPqHgjXdJsLfUdZ024ttPlcr5nBbjnpn9ag8ZafpVjfwnw6dUl0uSMbbnUIRGZnH3toHG0ZHc1CqRbsmNwaVzn6Q0Gg1oQJRRRQMKUdKSlFAH2J4S1o6tYRLNavbThDwSHVtuB95eB1HH+FbzYGBgEjvXzd8M/Gem6LMsdyL+2U9Wik8xPxU19DaTqFtqmmx3llKs8LLu3L/UdjXjOEovkaLzDDQhL29L4H+DHS3TRSZaM7DjDkj5iewFSeSzt86gqBnO47s56AelEu11B25ZDkcc1OnzoOAE6iuOMOeTjPUylV9nCMqSs+pTUXFpA32cC4RTlYyQucnJGauWjmW3SVozE7D5kJBK89DTyMke5qG7hMsLKkjxuRgOhIIpqEqTutUEq8MUlGpaMm9Zf5rb9SwOpyDQSSGwAf61mP8A2nbWe22m+1TLwPOUcr68d60YWZ4VZgu8gFgnQHuOffNVCsqr5VoZ18G8PH2nMpJ6af5Dh0A56UvYetIAOv5UufQ/hW1rI4dxc89KOcngUmeeKUcmlYY7PGOlJzx0JpAeTjApcf8A6qAE4PUcU1gCOf5U456A0oGeKlxKTIjyDmoliRU8tEVEUYAXgAe1WCpPPp6UnUY9O9ZuPc0UuxkajotlfjFxArY6cVhX3w+0m5GR5kZzkYArsTjrx+PpTJJEjGZJFUepOKlNR6nXSxOIWkGzzh/hZpI3lmkdsEJvH3T68VteGfBWj6DtkFu19eo++Myj5A3Y7fUepzVzUteuheCHStOkvFB+ZlBC/TNaOiprih31GDTocnKqpZnCk5xwcU41pPqehXp4mNLmrSSv0uk/8yl4z8J2/iqCJ9SuGSaHBVs4ijGcsNvckD7xNed/HzxToOpaTFpVnbHUbuDiC4jZlhsl4yF7OSFA9ABXtBRXBEoV+OhHy/lXjHxlsrWxtY7u2uTAJI3jdYgA3pgjuDnHboa3hUaqRi+vmZZbRhiW41JO8U7W28/y9D59NNpxpK905RKKKKBhS0lKOlAj1zUcTaja3lvaadZiC2S1MVvblVk2gDc3zck4r0XwrZWN9DZXdlBJp13EgEslvKcTeuVIxj2oor5upNtJnuQqzVNwTdl/Xz+Z3to7SIxJGE+Xp196sIcYB5JGaKK2pydkz5zEwSk0gGN+3HQZzS4G08UUU02c9kNZtodsZwCevWkjffGkmPvKDj04/wDr0UU5RT3BNrYevJH0oL4GQOmKKKzfux0GnzPUcG+bOM8ZoDcdO+KKKE9QkhobMjDn5QB14NPBzxjpRRVxdyGhGYB1GOv+FOzjiiigaGbssRilcfLkdqKK5YScm7nS0lFWECDIXJxyajFrAWBaJWPYsM4oorSNKD3RKr1I/C7EwOUBPPFJt5DDhvUUUVfKm0iVJq5HI2YyxGT0r57+Puou+rRWAQBYud+eWOP/AK9FFPDJSxUb9j2su93DVpLe36o8fpMUUV75wBSUUUALRRRTA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with episcleritis associated with inflammatory bowel disease showing the characteristic injection of the ciliary vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1089=[""].join("\n");
var outline_f1_4_1089=null;
var title_f1_4_1090="Spleen aspirate 1A answer";
var content_f1_4_1090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81163%7EID%2F59292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81163%7EID%2F59292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papanicoleau stain of a fine-needle aspirate of the spleen (x400) shows the broad-based, thick-walled dividing yeast forms of Blastomyces dermatitidis. Identification of this organism may also be made by fungal culture on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hua Jiang, MD and Joyce Fingeroth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lactophenol-blue wet mount of Blastomyces dermatitidis from a fungal culture on Sabouraud's agar (low power). Note the single stalked conidia along the septate hyphae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hua Jiang, MD and Joyce Fingeroth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1090=[""].join("\n");
var outline_f1_4_1090=null;
var title_f1_4_1091="Acral lentiginous melanoma 3";
var content_f1_4_1091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerated melanoma of the plantar surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1091=[""].join("\n");
var outline_f1_4_1091=null;
var title_f1_4_1092="Total parenteral nutrition: Patient drug information";
var content_f1_4_1092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Total parenteral nutrition: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     see \"Total parenteral nutrition: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to aid diet needs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amino acids, dextrose, fat emulsion, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to corn, corn products, eggs, or soybeans, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Irritation of the pancreas, very high cholesterol, or very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given in a hospital or doctor's office. If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12138 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1092=[""].join("\n");
var outline_f1_4_1092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026043\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026042\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026047\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026048\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026050\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026045\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026046\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026051\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026052\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=related_link\">",
"      Total parenteral nutrition: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_4_1093="Cholangiogram cuboidal bile duct stones";
var content_f1_4_1093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cholangiogram showing common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing multiple cuboidal-shaped stones in the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1093=[""].join("\n");
var outline_f1_4_1093=null;
var title_f1_4_1094="Mitoxantrone: Patient drug information";
var content_f1_4_1094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mitoxantrone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     see \"Mitoxantrone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12407?source=see_link\">",
"     see \"Mitoxantrone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mitoxantrone Injection&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease you may need a lower dose. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting some types of cancer. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mitoxantrone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had daunorubicin, doxorubicin, epirubicin, or idarubicin before, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids (urine) to blue or green.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, no period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10956 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1094=[""].join("\n");
var outline_f1_4_1094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197570\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028729\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028731\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028730\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028735\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028736\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028738\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028733\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028734\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028739\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028740\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=related_link\">",
"      Mitoxantrone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12407?source=related_link\">",
"      Mitoxantrone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_4_1095="Histology case 4";
var content_f1_4_1095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Histology case 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Which of these disorders is most compatible with the clinical history?",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1095=[""].join("\n");
var outline_f1_4_1095=null;
var title_f1_4_1096="Liposomal amphotericin B: Drug information";
var content_f1_4_1096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal amphotericin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/57/5013?source=see_link\">",
"    see \"Liposomal amphotericin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"    see \"Liposomal amphotericin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.V.: 3-6 mg/kg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses (7.5-15 mg/kg/day) have been used clinically in special cases (CDC [parameningeal], 2012; Kauffman, 2012; Walsh, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication: For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine;",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine;",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cryptococcal meningitis (HIV-positive):",
"     </b>",
"     6 mg/kg/day or 4-6 mg/kg/day in combination with addition of oral flucytosine 25 mg/kg 4 times daily (unlabeled combination; CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Empiric candidiasis therapy:",
"     </b>",
"     3-5 mg/kg/day (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"     I.V.: 3-5 mg/kg/day (with or without flucytosine 25 mg/kg 4 times daily) for 6 weeks after valve replacement;",
"     <b>",
"      Note:",
"     </b>",
"     If isolates susceptible and/or clearance demonstrated, guidelines recommend step-down to fluconazole; also for long-term suppression therapy if valve replacement is not possible (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Fungal sinusitis:",
"     </b>",
"     Limited data in immunocompromised patients have shown efficacy with 3-10 mg/kg/day (Barron, 2005; Pagano, 2004; Rokicka, 2006).",
"     <b>",
"      Note:",
"     </b>",
"     An azole antifungal is recommended if causative organism is",
"     <i>",
"      Aspergillus",
"     </i>",
"     spp or",
"     <i>",
"      Pseudallescheria boydii",
"     </i>",
"     (",
"     <i>",
"      Scedosporium",
"     </i>",
"     sp).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningitis (secondary to contaminated  [eg,",
"     </b>",
"     <b>",
"      <i>",
"       Exserohilum rostratum",
"      </i>",
"     </b>",
"     <b>",
"      ] steroid products), severe or in patients not improving with voriconazole monotherapy (unlabeled use)  (CDC [parameningeal], 2012; Kauffman, 2012):",
"     </b>",
"     I.V.: 5-6 mg/kg/day  in combination with voriconazole for &ge;3 months; a higher dose (7.5 mg/kg/day) may be considered in patients who are not improving.",
"     <b>",
"      Note:",
"     </b>",
"     Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Osteoarticular candidiasis:",
"     </b>",
"     I.V.: 3-5 mg/kg/day for several weeks, followed by fluconazole for 6-12 months (osteomyelitis) or 6 weeks (septic arthritis) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Osteoarticular infection (secondary to contaminated [eg,",
"     </b>",
"     <b>",
"      <i>",
"       Exserohilum rostratum",
"      </i>",
"     </b>",
"     <b>",
"      ] steroid products), severe or in patients with clinical instability (unlabeled use) (CDC [osteoarticular], 2012; Kauffman, 2012):",
"     </b>",
"     I.V.: 5 mg/kg/day in combination with voriconazole for &ge;3 months.",
"     <b>",
"      Note:",
"     </b>",
"     Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Systemic fungal infections",
"     </b>",
"     <b>",
"      <i>",
"       (Aspergillus, Candida, Cryptococcus):",
"      </i>",
"     </b>",
"     3-5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      General invasive Candidal disease:",
"     </i>",
"     3-5 mg/kg/day with oral flucytosine 25 mg/kg 4 times daily (unlabeled combination; Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Candidal meningitis:",
"     </i>",
"     3-5 mg/kg/day with oral flucytosine 25 mg/kg 4 times daily (unlabeled combination; Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Histoplasmosis (unlabeled use):",
"     </i>",
"     3-5 mg/kg/day (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Visceral leishmaniasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immunocompetent:",
"     </i>",
"     3 mg/kg/day on days 1-5, and 3 mg/kg/day on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternate regimen of 2 mg/kg/day for 5 days has been reportedly effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immunocompromised:",
"     </i>",
"     4 mg/kg/day on days 1-5, and 4 mg/kg/day on days 10, 17, 24, 31, and 38",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"      see \"Liposomal amphotericin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Children &ge;1 month: I.V.: 3-6 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Premedication:",
"     </b>",
"     For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine;",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine;",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"     Children &ge;1 month: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Empiric therapy:",
"     </b>",
"     3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Systemic fungal infections",
"     </b>",
"     <b>",
"      <i>",
"       (Aspergillus, Candida, Cryptococcus):",
"      </i>",
"     </b>",
"     3-5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Systemic fungal infections (HIV-exposed/-positive [CDC, 2009; unlabeled use]):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Aspergillosis:",
"     </i>",
"     5 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Candida, invasive:",
"     </i>",
"     5 mg/kg/day once daily (may consider addition of oral flucytosine for severe disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Cryptococcal meningitis:",
"     </i>",
"     4-6 mg/kg/day once daily plus oral flucytosine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Cryptococcus, disseminated (non-CNS):",
"     </i>",
"     3-5 mg/kg/day (may consider addition of oral flucytosine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Histoplasmosis:",
"     </i>",
"     3-5 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Visceral leishmaniasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immunocompetent:",
"     </i>",
"     3 mg/kg/day on days 1-5, and 3 mg/kg/day on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternate regimen of 10 mg/kg/day for 2 days has been reportedly effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immunocompromised:",
"     </i>",
"     4 mg/kg/day on days 1-5, and 4 mg/kg/day on days 10, 17, 24, 31, and 38",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     None necessary; effects of renal impairment are not currently known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AmBisome&reg;: 50 mg [contains soy, sucrose 900 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer via intravenous infusion, over a period of approximately 2 hours. Infusion time may be reduced to approximately 1 hour in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased. Administer at a rate of 2.5 mg/kg/hour. Existing intravenous line should be flushed with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to infusion (if not feasible, administer through a separate line). An in-line membrane filter (not less than 1 micron) may be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs, 30-60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen, choline magnesium trisalicylate) &plusmn; diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, other saline-containing solutions, or preservatives.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doripenem.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Empirical therapy for presumed fungal infection in febrile, neutropenic patients; treatment of patients with",
"     <i>",
"      Aspergillus",
"     </i>",
"     species,",
"     <i>",
"      Candida",
"     </i>",
"     species, and/or",
"     <i>",
"      Cryptococcus",
"     </i>",
"     species infections refractory to amphotericin B desoxycholate (conventional amphotericin), or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B desoxycholate; treatment of cryptococcal meningitis in HIV-infected patients; treatment of visceral leishmaniasis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F134897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of systemic",
"     <i>",
"      Histoplasmosis",
"     </i>",
"     infection; empiric treatment of fungal meningitis or osteoarticular infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lipid-based amphotericin formulations (AmBisome&reg;) may be confused with conventional formulations (Amphocin&reg;, Fungizone&reg;) or with other lipid-based amphotericin formulations (Abelcet&reg;, Amphotec&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentage of adverse reactions is dependent upon population studied and may vary with respect to premedications and underlying illness. Incidence of decreased renal function and infusion-related events are lower than rates observed with amphotericin B deoxycholate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (15%), edema (12% to 14%), tachycardia (9% to 19%), hypotension (7% to 14%), hypertension (8% to 20%), chest pain (8% to 12%), hypervolemia (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (29% to 48%), insomnia (17% to 22%), headache (9% to 20%), anxiety (7% to 14%), pain (14%), confusion (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5% to 25%), pruritus (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (31% to 51%), hypomagnesemia (15% to 50%), hyperglycemia (8% to 23%), hypocalcemia (5% to 18%), hyponatremia (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (16% to 40%), vomiting (11% to 32%), diarrhea (11% to 30%), abdominal pain (7% to 20%), constipation (15%), anorexia (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (27% to 48%), blood transfusion reaction (9% to 18%), leukopenia (15% to 17%), thrombocytopenia (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (7% to 22%), bilirubinemia (&le;18%), ALT increased (15%), AST increased (13%), liver function tests abnormal (not specified) (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (6% to 13%), back pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity (14% to 47%), creatinine increased (18% to 40%), BUN increased (7% to 21%), hematuria (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (18% to 23%), lung disorder (14% to 18%), cough (2% to 18%), epistaxis (9% to 15%), pleural effusion (13%), rhinitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infusion reactions (4% to 21%), sepsis (7% to 14%), infection (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, facial swelling, flushing, orthostatic hypotension, valvular heart disease, vascular disorder, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, abnormal thinking, coma, depression, dysesthesia, dizziness (7% to 9%), hallucinations, malaise, nervousness, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, dry skin, maculopapular rash, petechia, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, fluid overload, hypernatremia (4%), hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hypophosphatemia, hypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, amylase increased, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, gastrointestinal hemorrhage (10%), hematemesis, hemorrhoids, gum/oral hemorrhage, ileus, mucositis, rectal disorder, stomatitis, ulcerative stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulation disorder, hemorrhage, prothrombin decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatocellular damage, hepatomegaly, veno-occlusive liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone pain, dystonia, myalgia, neck pain, paresthesia, rigors, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, dry eyes, eye hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Abnormal renal function, acute renal failure, dysuria, renal failure, toxic nephropathy, urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, dry nose, hemoptysis, hyperventilation, pharyngitis, pneumonia, pulmonary edema, respiratory alkalosis, respiratory insufficiency, respiratory failure, sinusitis, hypoxia (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, cell-mediated immunological reaction, flu-like syndrome, graft-versus-host disease, herpes simplex, hiccup, procedural complication (8% to 10%), diaphoresis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Agranulocytosis, angioedema, bronchospasm, cyanosis/hypoventilation, erythema, hemorrhagic cystitis, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphotericin B deoxycholate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. Administer under close clinical observation during initial dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Acute reactions (including fever and chills) may occur 1-3 hours after starting infusions; reactions are more common with the first few doses and generally diminish with subsequent doses. Immediately discontinue infusion if severe respiratory distress occurs; the patient should not receive further infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antineoplastics: Concurrent use with antineoplastic agents may enhance the potential for renal toxicity, bronchospasm or hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxic drugs: Concurrent use of amphotericin B with other nephrotoxic drugs may enhance the potential for drug-induced renal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in patients &lt;1 month of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving simultaneous leukocyte transfusions and amphotericin B.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Amphotericin B may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6866584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (King, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6866586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended (Mactal-Haaf, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F14637213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     If on parenteral nutrition, may need to adjust the amount of lipid infused. The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg. (Sacks, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (AmBisome Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $196.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN and serum creatinine levels should be determined every other day while therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, hematocrit, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc); monitor cardiac function if used concurrently with corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome (AR, AT, AU, BE, CH, DE, DK, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, NL, NO, PL, PY, RU, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Amphotec (CL);",
"     </li>",
"     <li>",
"      Fengkesong (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 131 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 174 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barron MA, Lay M, Madinger NE, &ldquo;Surgery and Treatment with High-Dose Liposomal Amphotericin B for Eradication of Craniofacial Zygomycosis in a Patient with Hodgkin&rsquo;s Disease Who Had Undergone Allogeneic Hematopoietic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       J Clin Microbiol",
"      </i>",
"      , 2005, 43(4):2012-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/15815047/pubmed\" id=\"15815047\" target=\"_blank\">",
"        15815047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Adults and Adolescents.  Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Interim Treatment Guidance for Central Nervous System (CNS) and Parameningeal Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012.  Available at",
"      <a href=\"file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html\" target=\"_blank\">",
"       file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Interim Treatment Guidance for Osteoarticular Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012. Available at",
"      <a href=\"file://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html\" target=\"_blank\">",
"       file://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, \"Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards JE Jr, Bodey GP, Bowden RA, et al, &ldquo;International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1997, 25(1):43-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/9243032/pubmed\" id=\"9243032\" target=\"_blank\">",
"        9243032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eggimann P, Francioli P, Bille J, et al, &ldquo;Fluconazole Prophylaxis Prevents Intra-abdominal Candidiasis in High-Risk Surgical Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(6):1066-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/10397206/pubmed\" id=\"10397206\" target=\"_blank\">",
"        10397206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emminger W, Graninger W, Emminger-Schmidmeir W, et al, &ldquo;Tolerance of High Doses of Amphotericin B by Infusion of a Liposomal Formulation in Children With Cancer,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 1994, 68:27-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/8110875/pubmed\" id=\"8110875\" target=\"_blank\">",
"        8110875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fichtenbaum CJ, Zackin R, Rajicic N, et al, &ldquo;Amphotericin B Oral Suspension for Fluconazole-Refractory Oral Candidiasis in Persons With HIV Infection. Adult AIDS Clinical Trials Group Study Team 295,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2000, 14(7):845-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/10839593/pubmed\" id=\"10839593\" target=\"_blank\">",
"        10839593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galgiani JN, Ampel NM, Blair JE, et al, \"Coccidioidomycosis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/16206093/pubmed\" id=\"16206093\" target=\"_blank\">",
"        16206093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hiemenz JW and Walsh TJ, &ldquo;Lipid Formulations of Amphotericin B: Recent Progress and Future Directions,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(Suppl 2):133-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/8824978/pubmed\" id=\"8824978\" target=\"_blank\">",
"        8824978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, \"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Pappas PG, Patterson TF, &ldquo;Fungal Infections Associated With Contaminated Methylprednisolone Injections: Preliminary Report,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012 [epub ahead pf print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/23083312/pubmed\" id=\"23083312\" target=\"_blank\">",
"        23083312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King CT, Rogers PD, Cleary JD, et al, \"Antifungal Therapy During Pregnancy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1998, 27(5):1151-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/9827262/pubmed\" id=\"9827262\" target=\"_blank\">",
"        9827262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):9-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/1379913/pubmed\" id=\"1379913\" target=\"_blank\">",
"        1379913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mactal-Haaf C, Hoffman M, and Kuchta A, \"Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2001, 17(2):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/11847833/pubmed\" id=\"11847833\" target=\"_blank\">",
"        11847833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(25):2020-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/12490683/pubmed\" id=\"12490683\" target=\"_blank\">",
"        12490683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pagano L, Offidani M, Fianchi L, et al, &ldquo;Mucormycosis in Hematologic Patients,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2004, 89(2):207-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/15003897/pubmed\" id=\"15003897\" target=\"_blank\">",
"        15003897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1998, 73(12):1205-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/9868423/pubmed\" id=\"9868423\" target=\"_blank\">",
"        9868423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Bennett JE, and Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(20):1325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/7935701/pubmed\" id=\"7935701\" target=\"_blank\">",
"        7935701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Pappas PG, Karchmer AW, et al, &ldquo;A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole Plus Placebo Versus Fluconazole Plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(10):1221-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/12746765/pubmed\" id=\"12746765\" target=\"_blank\">",
"        12746765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Walsh TJ, Sobel JD, et al, &ldquo;Practice Guidelines for the Treatment of Candidiasis. Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 30(4):662-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/10770728/pubmed\" id=\"10770728\" target=\"_blank\">",
"        10770728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ringden O, Andstrom E, Remberger M, et al, &ldquo;Safety of Liposomal Amphotericin B (AmBisome&reg;) in 187 Transplant Recipients Treated With Cyclosporin,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1994, 14(Suppl 5):10-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rokicka M, &ldquo;AmBisome&reg; Treatment of Fungal Sinusitis in Severe Immunocompromised Patient With Acute Lymphoblastic Leukemia Relapsed after Autologous Peripheral Blood Transplantation,&rdquo;",
"      <i>",
"       ACTA Biomed",
"      </i>",
"      , 2006, 77(Suppl 2):26-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/16918064/pubmed\" id=\"16918064\" target=\"_blank\">",
"        16918064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacks GS and Cleary JD, &ldquo;Nutritional Impact of Lipid-Associated Amphotericin B Formulations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(1):121-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/8997484/pubmed\" id=\"8997484\" target=\"_blank\">",
"        8997484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):306-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/10221369/pubmed\" id=\"10221369\" target=\"_blank\">",
"        10221369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TH, Goodman JL, Pappas P, et al, &ldquo;Safety, Tolerability, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected With",
"      <i>",
"       Aspergillus",
"      </i>",
"      Species and Other Filamentous Fungi: Maximum Tolerated Dose Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(12):3487-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/11709329/pubmed\" id=\"11709329\" target=\"_blank\">",
"        11709329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Finberg RW, Arndt C, et al, &ldquo;Liposomal Amphotericin B for Empirical Therapy in Patients With Persistent Fever and Neutropenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(10):764-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/10072411/pubmed\" id=\"10072411\" target=\"_blank\">",
"        10072411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al, \"Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/4/1096/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9499 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1096=[""].join("\n");
var outline_f1_4_1096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134901\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134884\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134894\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134885\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134886\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134867\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134852\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134869\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134908\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134868\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134897\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134910\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134899\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134872\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134856\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298746\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134863\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866584\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134890\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866586\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14637213\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322989\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134865\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038526\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134855\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134871\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/57/5013?source=related_link\">",
"      Liposomal amphotericin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=related_link\">",
"      Liposomal amphotericin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_4_1097="Management of the open abdomen in adults";
var content_f1_4_1097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the open abdomen in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Niels Martin, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Babak Sarani, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1097/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/4/1097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H632146272\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;open abdomen&rdquo; refers to a defect in the abdominal wall that exposes the abdominal viscera. Damage control surgery associated with trauma and abdominal compartment syndrome is the most frequent reason for open abdomen. Open abdomen exposes the viscera and leads to fluid and heat loss, which can be reduced with temporary abdominal closure until the abdomen can be closed primarily, closed functionally, or graft coverage of the exposed viscera provided.",
"   </p>",
"   <p>",
"    The care of the patient with an open abdomen, techniques for placement of temporary abdominal dressings and timing and methods of abdominal closure will be reviewed here. The diagnosis and management of abdominal compartment syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632146279\">",
"    <span class=\"h1\">",
"     OPEN ABDOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open abdomen is an abdominal wall defect created by intentionally leaving an abdominal incision open at the completion of surgery or by opening (or re-opening) the abdomen because of concern for abdominal compartment syndrome. Open abdomen may also be the result of injuries to the abdominal wall that produce significant soft tissue defects.",
"   </p>",
"   <p>",
"    Open abdomen is managed with temporary abdominal closure using one of several techniques, followed by interval abdominal closure, preferably by bringing the edges of the abdominal fascia together primarily (primary closure) or, if this is not feasible, using a functional closure or simple coverage. The techniques of temporary closure and closure of the abdomen are discussed below. (See",
"    <a class=\"local\" href=\"#H632146314\">",
"     'Temporary abdominal closure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H632146444\">",
"     'Abdominal closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255249462\">",
"    <span class=\"h2\">",
"     Etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common circumstances that result in open abdomen include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67794622\">",
"    <span class=\"h3\">",
"     Damage control surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage control is an operative strategy that is used to manage immediately life-threatening conditions by delaying definitive management of less severe injuries until the patient is physiologically capable of withstanding",
"    <span class=\"nowrap\">",
"     repair/reconstruction.",
"    </span>",
"    This strategy is used most frequently in severely injured or critically ill patients who are hemodynamically unstable. Because a repeat procedure is required for definitive repair, the abdomen is left open to facilitate reexploration which is delayed until hypovolemia, hypothermia and coagulopathy are corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Leaving the abdomen open also obviates abdominal compartment syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67794629\">",
"    <span class=\"h3\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-abdominal hypertension (IAH) and abdominal compartment syndrome can be due to any process that increases the volume of the confined space of the abdominal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Increased volume in the abdomen is typically the result of an increase in interstitial fluid as is seen with large volume resuscitation, but space occupying fluid (blood or ascites) in the peritoneum or retroperitoneum can also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/9\">",
"     9",
"    </a>",
"    ]. Abdominal compartment syndrome, including its etiology and strategies for prevention, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H7#H7\">",
"     \"Abdominal compartment syndrome\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67794601\">",
"    <span class=\"h3\">",
"     Septic abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel perforation with severe contamination of the peritoneal cavity can result in recurrent intra-abdominal sepsis and postoperative abscess formation in spite of aggressive abdominal irrigation. Under this circumstance, it may be desirable to leave the abdominal wall open and use negative-pressure wound therapy to remove residual or reaccumulated fluid or pus. The temporary abdominal dressing facilitates access for repeated abdominal exploration and abdominal irrigation, as needed, until bacterial counts are reduced and closure can be performed. This management strategy is associated with a reduced risk of postoperative infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H174061378#H174061378\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Delayed closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67794608\">",
"    <span class=\"h3\">",
"     Refractory intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more controversial indication for open abdomen is refractory intracranial hypertension associated with traumatic brain injury. This indication is based upon case reports and small case series that suggest that the abdominal decompression lowers venous pressures augmenting venous outflow from the head and decreasing intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of acute severe traumatic brain injury\", section on 'Intracranial pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255249176\">",
"    <span class=\"h2\">",
"     Complications of open abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leaving the abdomen open, when indicated, is beneficial but is also associated with complications related to fluid efflux from the abdomen, exposure of the bowel, and abdominal muscle retraction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid loss &ndash; A significant amount of fluid can be lost through an open abdomen. If a closed suction system is used as a part of the temporary abdominal closure, this fluid can be quantified and included in the assessment of daily fluid balance and the patient&rsquo;s fluid intake adjusted to prevent hypovolemia. Some temporary abdominal closure systems do not have the ability to collect and quantify fluid losses (eg, Bogota bag). (See",
"      <a class=\"local\" href=\"#H255251446\">",
"       'Techniques'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Protein loss &ndash; The fluid that is secreted by the peritoneum is rich in protein with about 2 grams of protein lost from the abdomen for each liter of fluid removed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/13\">",
"       13",
"      </a>",
"      ]. These losses must be accounted for in the patient&rsquo;s nutrition plan. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"       \"Perioperative nutritional support\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fistula formation &ndash; With open abdomen, the bowel is frequently manipulated and is at risk for injury [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. The incidence of entero-cutaneous or entero-atmospheric fistula may be as high as 20 percent and can occur as early as eight days from the initial laparotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Patients with a bowel anastomosis are at the highest risk. Whenever possible, bowel anastomoses should be covered by omentum or other viscera and protected from exposure to air as well as any materials associated with the temporary abdominal closure.",
"     </li>",
"     <li>",
"      Loss of domain &ndash; With open abdomen from a midline abdominal incision, the musculature of the abdominal wall retracts the fascia laterally. Once the indication for the open abdomen has resolved, the fascia (and sometimes skin) may not be able to be brought back to the midline for primary closure, resulting in a large ventral hernia (",
"      <a class=\"graphic graphic_picture graphicRef78618 \" href=\"UTD.htm?32/21/33106\">",
"       picture 1",
"      </a>",
"      ). The use of a negative pressure wound system helps to counteract the lateral forces on the abdominal wall and may allow primary closure of the fascia and skin or, if primary closure is not possible, at least decreases the size of the resultant hernia. The repair of incisional hernia is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of abdominal hernias\", section on 'Incisional hernia'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H632146335\">",
"       'Negative pressure wound systems'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632146314\">",
"    <span class=\"h1\">",
"     TEMPORARY ABDOMINAL CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision has been made to leave the abdomen open (or re-open it), the abdominal defect must be covered, which is termed temporary abdominal closure. The main goal of temporary abdominal closure is to control fluid losses and minimize the loss of domain. It is important to remember that even with a temporary abdominal closure in place, intraabdominal pressure can increase and abdominal compartment syndrome can recur [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255251446\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques for temporary abdominal closure are available, including patch closure, negative pressure systems (towel and sponge-based), and silo closure. Each of these techniques has advantages and disadvantages with respect to their ability to control fluid loss, frequency of dressing changes, minimizing loss of domain, ease of use, and cost. The patch or silo technique can be used alone or in combination with a negative pressure system. Skin-only closures are an option but are rarely used in contemporary practice.",
"   </p>",
"   <p>",
"    The ideal technique for temporary abdominal closure, interval between fascial closure attempts, or the number of closure attempts until an alternative strategy is tried has not been well studied. The authors prefer to start with a commercial negative pressure device to control and quantitate fluid efflux from the abdomen between operative attempts at fascial closure performed every 48 hours. The applied negative pressure counteracts some of the lateral forces responsible for loss of abdominal domain; however, additional adjunctive techniques may be needed to help bring the fascial edges to the midline to improve the rates of primary closure. (See",
"    <a class=\"local\" href=\"#H170878938\">",
"     'Adjunctive techniques'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H170879412\">",
"     'Rates of primary fascial closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255249609\">",
"    <span class=\"h3\">",
"     Patch techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch closure of the abdomen refers to the interposition of prosthetic material between the edges of the fascia and suturing it into place. Two main patch techniques are used to provide abdominal closure and allow easy re-entry into the abdomen. Although patching can minimize fascial retraction, control of fluid is suboptimal, and thus, patch techniques are often used in conjunction with a negative pressure system to prevent skin maceration and simplify wound care. (See",
"    <a class=\"local\" href=\"#H632146335\">",
"     'Negative pressure wound systems'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The main disadvantage of patch closure is the potential for fascial necrosis due to excess traction on the fascia, or repeated fascial suturing. Any fascial loss decreases the likelihood of future primary fascial closure. Other closure techniques that do not require manipulation of the fascia until closure may be preferred, particularly if the integrity of the fascial tissue is compromised.",
"   </p>",
"   <p>",
"    The features of the two most commonly used patch systems are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wittmann patch &ndash; The Wittmann Patch sheet is sutured to the fascia of the abdominal wall laterally, and closure of the patch at the midline is accomplished with a velcro-like closure (one sheet with hooks and the other with loops). As edema resolves, the hook and loop sheets are re-adjusted to gradually bring the fascia toward the midline. Thus, this technique can also be considered a dynamic fascial closure technique. The Wittmann Patch significantly improves delayed primary fascial closure rates [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H170879412\">",
"       'Rates of primary fascial closure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Polytetrafluoroethylene patch &ndash; A polytetrafluoroethylene (PTFE) patch can also be used for temporary closure. The patch is anchored to the fascia laterally, and serial plication of the patch at the midline progressively brings the fascial edges together [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632146335\">",
"    <span class=\"h3\">",
"     Negative pressure wound systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of negative pressure wound therapy (NPWT) dressings, also known as vacuum-assisted closure (VAC), is an alternative and frequently-employed technique for temporary abdominal closure. The application of negative pressure opposes the lateral retraction of the abdominal musculature minimizing loss of domain and improves the likelihood of primary fascial closure. (See",
"    <a class=\"local\" href=\"#H170879412\">",
"     'Rates of primary fascial closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An inert layer (towel adhered to an adhesive sheet or elastic sponge) is placed to protect the abdominal viscera and an elastic self-adhesive sheet secured to the lateral abdominal wall to which a suction system is incorporated. These wound systems are customizable and are excellent at controlling abdominal fluid.",
"   </p>",
"   <p>",
"    The general mechanism of action of NPWT, its clinical uses and contraindications, and placement and management of the device are discussed in detail elsewhere. The effectiveness of using NPWT in the management of the open abdomen is discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The essential differences between towel-based and sponge-based negative pressure systems are described briefly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41357434\">",
"    <span class=\"h4\">",
"     Towel-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Towel-based negative pressure systems (&ldquo;Barker&rsquo;s VAC&rdquo;) use a surgical towel adhered to a polyethylene sheet (eg, Ioban&trade;) that is placed between the viscera and posterior aspect of the anterior abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef55934 \" href=\"UTD.htm?15/37/15954\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67674 \" href=\"UTD.htm?30/61/31700\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Small slit perforations are made in the elastic drape to allow transfer of fluid out of the abdomen. Drain tubing is placed over the towel to capture the fluid and is connected to a closed-suction drainage system. An outer, adherent elastic layer is placed to cover the abdominal wall defect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/25,27,28,30\">",
"     25,27,28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Towel-based system dressings are easy to apply and inexpensive. Although the system effectively controls abdominal fluid, it does not provide effective suction throughout the abdomen, and thus, fluid can accumulate within the abdominal cavity. However, mild increases in intraabdominal volume can be accommodated without resulting in increased intraabdominal pressure because the system is relatively compliant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41357441\">",
"    <span class=\"h4\">",
"     Sponge-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available kits (Ab-Thera and VAC therapy) contain a perforated silastic sheet to place between the bowel and abdominal wall. A sponge is trimmed and used to fill the subcutaneous abdominal defect and an outer self-adherent skin drape contains a suction port that is connected to a proprietary suction device (",
"    <a class=\"graphic graphic_picture graphicRef79627 \" href=\"UTD.htm?0/19/307\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/31\">",
"     31",
"    </a>",
"    ]. Sponge-based systems are more expensive than the towel-based negative pressure system discussed above but provide more uniform suction throughout the peritoneal cavity, and may be more effective in preventing intraabdominal fluid accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41357998\">",
"    <span class=\"h3\">",
"     Silo techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silo techniques involve suturing a large, sterilized translucent bag to the abdominal fascia or skin. A Bogota Bag&trade; (",
"    <a class=\"graphic graphic_picture graphicRef77077 \" href=\"UTD.htm?40/34/41519\">",
"     picture 4",
"    </a>",
"    ), intravenous, dialysate, or irrigation bag can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/32\">",
"     32",
"    </a>",
"    ]. The technique is simple, low cost, and the translucent bag allows visual inspection of the abdominal viscera. However, the technique is more time-consuming compared with other techniques, fluid losses are difficult to control, and increased intra-abdominal pressure requires upsizing of the system, which requires operative replacement with a larger bag.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41357891\">",
"    <span class=\"h3\">",
"     Skin-only closures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin-only closures using towel clamps (",
"    <a class=\"graphic graphic_picture graphicRef57668 \" href=\"UTD.htm?40/29/41425\">",
"     picture 5",
"    </a>",
"    ) or staples to reapproximate the skin were the first methods for temporary closure of the abdominal",
"    <span class=\"nowrap\">",
"     wall/skin.",
"    </span>",
"   </p>",
"   <p>",
"    The disadvantages of skin-only closure are that it does not control fluid from the wound, the technique introduces artifacts into radiographic studies, and abdominal compartment syndrome can occur (or recur). Given other, more superior options, we avoid skin-only closure, whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170878938\">",
"    <span class=\"h2\">",
"     Adjunctive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other adjunctive techniques may help pull the fascia to the midline and facilitate primary fascial closure. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vessel loops placing traction on the skin (",
"      <a class=\"graphic graphic_picture graphicRef58493 \" href=\"UTD.htm?43/46/44783\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Commercial fascial closure systems (eg, Abdominal Re-approximation and Anchor System [ABRA]) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fascial tension sutures (ie, retention sutures) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Other improvised, noncommercial fascial tension devices",
"     </li>",
"     <li>",
"      Primary fascial release (relaxing incisions of the fascia of the oblique musculature)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An adjunctive technique is usually needed to supplement the suction force delivered by commercial negative pressure systems to counteract the lateral abdominal forces. However, care should be taken to minimize excessive fascial manipulation and tension, which can result in fascial injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255251544\">",
"    <span class=\"h2\">",
"     Ostomy placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ostomies often interfere with the placement of temporary abdominal closure devices and, as a result, reduce the rates of primary fascial closure or functional closure.",
"   </p>",
"   <p>",
"    A stoma that is matured (opening the blind end of the bowel and suturing to the skin) through the rectus muscle interferes with the placement and function of temporary abdominal closure dressings. Conversely, the abdominal dressing can prevent the proper placement and seal of the stoma appliance leading to leakage of bowel contents onto the open wound.",
"   </p>",
"   <p>",
"    To avoid these problems, whenever an ileostomy or colostomy are needed in conjunction with an open abdomen, we prefer to bring the small bowel or colon through the abdominal wall lateral to the rectus abdominus muscle through the oblique muscles, even though the incidence of parastomal hernia may be greater using this placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If maturation of the stoma can be delayed for a short period of time (on the order of days), temporary closure tends to be easier and a primary closure or a functional closure is more likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255250676\">",
"    <span class=\"h1\">",
"     CARE OF THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following temporary abdominal closure, the patient is monitored in the intensive care unit. Abdominal dressings associated with the closure (adhesive dressings, gauze, negative pressure systems) are changed, as needed, and the abdominal contents inspected every two to three days in the intensive care unit or operating room depending upon the condition of the patient and indication for the open abdomen. Dressings and abdominal inspections are continued until abdominal closure is feasible and safe.",
"   </p>",
"   <p>",
"    Many patients remain intubated due to the severity of illness that led to the need for the open abdomen; however, the presence of an open abdomen does not mandate mechanical ventilation. If the patient needs to return to the operating room for a second look, washout, or other surgical procedure, the decision to have the patient remain intubated in the interim or to extubate the patient depends on multiple factors (eg, comorbidities, associated injuries).",
"   </p>",
"   <p>",
"    The intubated patient with an open abdomen does not need to be deeply sedated or paralyzed; spontaneous breathing on the ventilator is allowed. Light sedation (Richmond Agitation-Sedation Scale [RASS] score between -2 to 0 (",
"    <a class=\"graphic graphic_table graphicRef57874 \" href=\"UTD.htm?4/34/4653\">",
"     table 1",
"    </a>",
"    )) should be sufficient to keep the temporary abdominal dressing in place and prevent evisceration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/37\">",
"     37",
"    </a>",
"    ]. However, forceful Valsalva efforts, as can occur with severe agitation or delirium, may disrupt a temporary abdominal closure potentially leading to evisceration. These patients may need to be more deeply sedated to maintain the dressings. Once the patient no longer requires frequent operative intervention, the patient can be weaned from the ventilator, usually after one week of open abdomen management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient is taken back to the operating room, typically every two to three days. There are no data to support a specific interval and every clinical situation is different. A shorter interval between operative interventions may be physiologically challenging for the patient, whereas longer intervals may allow the formation of adhesions increasing the risk of bowel injury.",
"   </p>",
"   <p>",
"    Assuming no contraindications (eg, ileus), enteral nutrition is permissible with an open abdomen and temporary abdominal closure dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the need for repeated return to the operating room frequently leads to holding tube feeds and nutritional goals may not be met. Under these circumstances, a combination of enteral and parenteral nutrition should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632146444\">",
"    <span class=\"h1\">",
"     ABDOMINAL CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each time the patient is returned to the operating room, the abdomen is assessed for potential closure. If closure cannot be performed, the temporary abdominal closure dressing is replaced with the fascial edges brought together as closely as possible and a return to the operating room planned in another 48 hours. In a review of 344 trauma patients with an open abdomen for damage control, abdominal fascial closure was achieved in 63 percent of the patients at the second look procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for ongoing fluid resuscitation or the development of a systemic inflammatory response will delay the time for fascial approximation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Fascial closure may not be possible under these circumstances.",
"   </p>",
"   <p>",
"    Generally speaking, the longer the abdomen remains open, the less likely primary fascial or functional closure will be achieved. With time, the fascia retracts further from the midline and the underlying bowel becomes adherent to the peritoneal cavity. Complications also increase as the interval from initial operative intervention to attempted closure increases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H255249176\">",
"     'Complications of open abdomen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If fascial closure is repeatedly unsuccessful, functional closure or intentional hernia with abdominal wall coverage can be used instead at any point in time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255251569\">",
"    <span class=\"h2\">",
"     Fascial closure techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideal management of the open abdomen results in closure that brings the edges of the abdominal fascia together primarily (primary closure). If this is not feasible, functional closure or simple coverage can be provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255250583\">",
"    <span class=\"h3\">",
"     Primary fascial closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure of the fascia refers to the direct approximation of the fascial edges to each other and is associated with the lowest rate of complications following management of the open abdomen. However, the late incidence of ventral hernia following primary fascial closure for open abdomen can be as high as 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the high hernia rate, biologic mesh reinforcement during primary fascial closure is frequently used. Permanent mesh is contraindicated if there are risk factors for mesh infection (eg, wound soilage). A component separation of the abdominal wall layers can also be used to provide fascial apposition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Techniques for ventral hernia repair are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32294?source=see_link\">",
"     \"Principles of component separation technique for complex abdominal wall defects and hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255250576\">",
"    <span class=\"h3\">",
"     Functional closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional closure refers to the bridging of a residual fascial defect with a biologic mesh (in-lay technique). The biologic mesh serves as a scaffold that is repopulated with host cells, which creates new native fascial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Once the biologic mesh is placed, the skin is closed over surgical drains placed into the subcutaneous space. Functional closure should not be attempted if the skin cannot be closed over the biologic mesh layer because exposed mesh is at risk for accelerated degradation and infection until a granulation tissue layer forms over the biologic mesh, which is a slow process that can take weeks.",
"   </p>",
"   <p>",
"    The late incidence of ventral hernia for functional abdominal closure to manage open abdomen has not been determined. One study that used acellular dermal matrix for ventral hernia repair noted an 80 percent hernia incidence over a mean follow-up of 21.4 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 37 patients, abdominal closure using a human acellular dermal matrix was possible in all patients who had an open abdomen for damage control indications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/49\">",
"     49",
"    </a>",
"    ]. These authors noted no complications when closure was performed &ldquo;early&rdquo;; early was not defined directly by the authors but the mean duration of open abdomen in this study was 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255250177\">",
"    <span class=\"h3\">",
"     Planned ventral hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If primary fascial closure or functional closure cannot be achieved, then planned ventral hernia is the only option. Skin coverage over abdominal viscera can be accomplished in one of two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin-only closure",
"      <strong>",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      A skin-only closure approximates the skin over the fascial defect leaving a ventral hernia. Primary skin closure requires close observation to watch for wound disruption that might lead to evisceration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H20#H20\">",
"       \"Principles of abdominal wall closure\", section on 'Skin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Split-thickness skin graft",
"      <strong>",
"      </strong>",
"      &ndash; If the skin cannot be approximated, the viscera within the wound are allowed to adhere to each other and to the abdominal wall. Once the abdominal contents have &ldquo;solidified&rdquo; and there is a healthy bed of granulation tissue overlying the bowel (",
"      <a class=\"graphic graphic_picture graphicRef70333 \" href=\"UTD.htm?13/26/13734\">",
"       picture 7",
"      </a>",
"      ), a split-thickness skin graft can be placed (",
"      <a class=\"graphic graphic_picture graphicRef78618 \" href=\"UTD.htm?32/21/33106\">",
"       picture 1",
"      </a>",
"      ). Occasionally, an absorbable (eg, Vicryl&trade;) mesh is sutured to the skin to prevent evisceration while awaiting granulation. Before elective hernia repair is attempted, 6 to 12 months are generally allowed to elapse following placement of a split-thickness skin graft. The interval of time allows maturation and dissolution of abdominal adhesions with a lower incidence of enterotomy during hernia repair [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268846#H55268846\">",
"       \"Basic principles of wound management\", section on 'Skin grafts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170879412\">",
"    <span class=\"h2\">",
"     Rates of primary fascial closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews have identified two small randomized trials, and other retrospective studies reporting rates of primary fascial closure and complication rates for the various temporary abdominal closure techniques described above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. No randomized trials are available directly comparing these techniques. One of the randomized trials compared negative pressure wound systems with synthetic mesh closure, which we do not advocate, and the other to retention sutures, which we use primarily as an adjunctive technique, if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H170878938\">",
"     'Adjunctive techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Representative mean rates for primary fascial closure are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      90 percent: Wittmann Patch (4",
"      <span class=\"nowrap\">",
"       studies/180",
"      </span>",
"      patients)",
"     </li>",
"     <li>",
"      85 percent: Dynamic fascial closure (1",
"      <span class=\"nowrap\">",
"       study/15",
"      </span>",
"      patients)",
"     </li>",
"     <li>",
"      60 percent: Sponge-based negative pressure system (8",
"      <span class=\"nowrap\">",
"       studies/251",
"      </span>",
"      patients) &nbsp;",
"     </li>",
"     <li>",
"      52 percent: Towel-based negative pressure system (15",
"      <span class=\"nowrap\">",
"       studies/1186",
"      </span>",
"      patients)",
"     </li>",
"     <li>",
"      29 percent: Silo technique (3",
"      <span class=\"nowrap\">",
"       studies/109",
"      </span>",
"      patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since this systematic review, two other small studies have reviewed the use of the Wittmann Patch finding primary fascial closure rates of 78 and 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/21,56\">",
"     21,56",
"    </a>",
"    ]. Although the Wittmann Patch has the highest average rate of primary fascial closure compared with other techniques, this temporary closure technique, when used alone, does not adequately manage fluid loss. (See",
"    <a class=\"local\" href=\"#H255249609\">",
"     'Patch techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some studies have reported rates for primary fascial closure using negative pressure systems that are higher than those reported in the systematic review above; however, rates range widely from 22 to 91 percent, reflecting heterogeneity in the study populations as well as methodology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/52\">",
"     52",
"    </a>",
"    ]. As an example, a retrospective review evaluating 104 patients found significantly higher primary fascial closure rates for negative pressure (vacuum-assisted) systems compared with those that provided no form of abdominal tension (78 versus 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating dynamic fascial closure with or without other techniques reported primary closure rates of 61 to 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In a multicenter study of 111 patients requiring long-term management for open abdomen (&gt;5 days), and managed with sponge-based negative pressure and mesh-mediated fascial traction, primary fascial closure was achieved in 69 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1097/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255249994\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term &ldquo;open abdomen&rdquo; refers to a defect in the abdominal wall that exposes the abdominal viscera. Open abdomen is often created intentionally by leaving an abdominal incision open at the completion of surgery or by opening (or re-opening) the abdomen because of abdominal compartment syndrome. (See",
"      <a class=\"local\" href=\"#H632146272\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H632146279\">",
"       'Open abdomen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open abdomen leads to fluid and protein losses. With prolonged open abdomen, bowel fistulization and loss of abdominal domain can complicate management. The main goal of temporary abdominal closure techniques is to control fluid losses and minimize the loss of domain. (See",
"      <a class=\"local\" href=\"#H255249176\">",
"       'Complications of open abdomen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several techniques for temporary abdominal closure are available, including patch closure, negative pressure systems (towel- and sponge-based), and silo closure. Each technique has advantages and disadvantages with respect to their ability to control fluid loss, frequency of dressing changes, minimizing loss of domain, ease of use, and cost. (See",
"      <a class=\"local\" href=\"#H255251446\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following temporary abdominal closure, the patient is monitored in the intensive care unit. Abdominal dressings associated with the closure (adhesive dressings, gauze, negative pressure systems) are changed, as needed, and the abdominal contents inspected every two to three days in the intensive care unit or operating room depending upon the condition of the patient and indication for the open abdomen. Dressings and abdominal inspections are continued until abdominal closure is feasible and safe. (See",
"      <a class=\"local\" href=\"#H255250676\">",
"       'Care of the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Wittmann Patch has the highest average rate of primary fascial closure compared with other techniques in observational studies. However, this temporary closure technique, when used alone, does not adequately manage fluid loss. (See",
"      <a class=\"local\" href=\"#H170879412\">",
"       'Rates of primary fascial closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using a negative pressure system (towel or sponge based) to control and quantify fluid loss (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Negative pressure systems can be used alone, or in conjunction with other temporary abdominal closure techniques. The applied negative pressure counteracts some of the lateral forces responsible for loss of abdominal domain; however, additional adjunctive techniques may be needed to help bring the fascial edges to the midline to improve the rates of primary closure. (See",
"      <a class=\"local\" href=\"#H632146335\">",
"       'Negative pressure wound systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the indication for the open abdomen has resolved, the abdomen is closed, preferably with a primary fascial closure. If primary fascial closure cannot be achieved, functional closure can be performed using a biologic mesh in-lay technique which generates new fascial tissue between the native fascial edges; however, the risk of subsequent hernia with this technique is high. If the gap between the fascial edges is too wide for a functional closure, primary skin closure can be performed, or skin grafts placed to cover the fascial defect once a layer of granulation tissue has developed over the consolidated visceral mass. (See",
"      <a class=\"local\" href=\"#H255251569\">",
"       'Fascial closure techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/1\">",
"      Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/2\">",
"      Abikhaled JA, Granchi TS, Wall MJ, et al. Prolonged abdominal packing for trauma is associated with increased morbidity and mortality. Am Surg 1997; 63:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/3\">",
"      Holcomb JB. Damage control resuscitation. J Trauma 2007; 62:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/4\">",
"      Sagraves SG, Toschlog EA, Rotondo MF. Damage control surgery--the intensivist's role. J Intensive Care Med 2006; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/5\">",
"      Fietsam R Jr, Villalba M, Glover JL, Clark K. Intra-abdominal compartment syndrome as a complication of ruptured abdominal aortic aneurysm repair. Am Surg 1989; 55:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/6\">",
"      Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol 2011; 22:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/7\">",
"      Ivatury RR. Update on open abdomen management: achievements and challenges. World J Surg 2009; 33:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/8\">",
"      Cheatham ML. Abdominal compartment syndrome. Curr Opin Crit Care 2009; 15:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/9\">",
"      Rodas EB, Malhotra AK, Chhitwal R, et al. Hyperacute abdominal compartment syndrome: an unrecognized complication of massive intraoperative resuscitation for extra-abdominal injuries. Am Surg 2005; 71:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/10\">",
"      Holzheimer RG, Gathof B. Re-operation for complicated secondary peritonitis - how to identify patients at risk for persistent sepsis. Eur J Med Res 2003; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/11\">",
"      Agalar F, Eroglu E, Bulbul M, et al. Staged abdominal repair for treatment of moderate to severe secondary peritonitis. World J Surg 2005; 29:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/12\">",
"      Joseph DK, Dutton RP, Aarabi B, Scalea TM. Decompressive laparotomy to treat intractable intracranial hypertension after traumatic brain injury. J Trauma 2004; 57:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/13\">",
"      Cheatham ML, Safcsak K, Brzezinski SJ, Lube MW. Nitrogen balance, protein loss, and the open abdomen. Crit Care Med 2007; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/14\">",
"      Mayberry JC, Burgess EA, Goldman RK, et al. Enterocutaneous fistula and ventral hernia after absorbable mesh prosthesis closure for trauma: the plain truth. J Trauma 2004; 57:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/15\">",
"      Ramsay PT, Mejia VA. Management of enteroatmospheric fistulae in the open abdomen. Am Surg 2010; 76:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/16\">",
"      Rao M, Burke D, Finan PJ, Sagar PM. The use of vacuum-assisted closure of abdominal wounds: a word of caution. Colorectal Dis 2007; 9:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/17\">",
"      Miller RS, Morris JA Jr, Diaz JJ Jr, et al. Complications after 344 damage-control open celiotomies. J Trauma 2005; 59:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/18\">",
"      Ertel W, Oberholzer A, Platz A, et al. Incidence and clinical pattern of the abdominal compartment syndrome after \"damage-control\" laparotomy in 311 patients with severe abdominal and/or pelvic trauma. Crit Care Med 2000; 28:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/19\">",
"      Gracias VH, Braslow B, Johnson J, et al. Abdominal compartment syndrome in the open abdomen. Arch Surg 2002; 137:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/20\">",
"      Wittmann DH, Aprahamian C, Bergstein JM, et al. A burr-like device to facilitate temporary abdominal closure in planned multiple laparotomies. Eur J Surg 1993; 159:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/21\">",
"      Weinberg JA, George RL, Griffin RL, et al. Closing the open abdomen: improved success with Wittmann Patch staged abdominal closure. J Trauma 2008; 65:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/22\">",
"      Cipolla J, Stawicki SP, Hoff WS, et al. A proposed algorithm for managing the open abdomen. Am Surg 2005; 71:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/23\">",
"      Nagy KK, Fildes JJ, Mahr C, et al. Experience with three prosthetic materials in temporary abdominal wall closure. Am Surg 1996; 62:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/24\">",
"      Vertrees A, Kellicut D, Ottman S, et al. Early definitive abdominal closure using serial closure technique on injured soldiers returning from Afghanistan and Iraq. J Am Coll Surg 2006; 202:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/25\">",
"      Barker DE, Kaufman HJ, Smith LA, et al. Vacuum pack technique of temporary abdominal closure: a 7-year experience with 112 patients. J Trauma 2000; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/26\">",
"      Navsaria PH, Bunting M, Omoshoro-Jones J, et al. Temporary closure of open abdominal wounds by the modified sandwich-vacuum pack technique. Br J Surg 2003; 90:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/27\">",
"      Brock WB, Barker DE, Burns RP. Temporary closure of open abdominal wounds: the vacuum pack. Am Surg 1995; 61:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/28\">",
"      Smith LA, Barker DE, Chase CW, et al. Vacuum pack technique of temporary abdominal closure: a four-year experience. Am Surg 1997; 63:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/29\">",
"      Barker DE, Green JM, Maxwell RA, et al. Experience with vacuum-pack temporary abdominal wound closure in 258 trauma and general and vascular surgical patients. J Am Coll Surg 2007; 204:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/30\">",
"      Sherck J, Seiver A, Shatney C, et al. Covering the \"open abdomen\": a better technique. Am Surg 1998; 64:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/31\">",
"      Miller PR, Meredith JW, Johnson JC, Chang MC. Prospective evaluation of vacuum-assisted fascial closure after open abdomen: planned ventral hernia rate is substantially reduced. Ann Surg 2004; 239:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/32\">",
"      Fernandez L, Norwood S, Roettger R, Wilkins HE 3rd. Temporary intravenous bag silo closure in severe abdominal trauma. J Trauma 1996; 40:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/33\">",
"      Urbaniak RM, Khuthaila DK, Khalil AJ, Hammond DC. Closure of massive abdominal wall defects: a case report using the abdominal reapproximation anchor (ABRA) system. Ann Plast Surg 2006; 57:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/34\">",
"      Verdam FJ, Dolmans DE, Loos MJ, et al. Delayed primary closure of the septic open abdomen with a dynamic closure system. World J Surg 2011; 35:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/35\">",
"      Kafka-Ritsch R, Zitt M, Schorn N, et al. Open abdomen treatment with dynamic sutures and topical negative pressure resulting in a high primary fascia closure rate. World J Surg 2012; 36:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/36\">",
"      Cothren CC, Moore EE, Johnson JL, et al. One hundred percent fascial approximation with sequential abdominal closure of the open abdomen. Am J Surg 2006; 192:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/37\">",
"      Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/38\">",
"      Byrnes MC, Reicks P, Irwin E. Early enteral nutrition can be successfully implemented in trauma patients with an \"open abdomen\". Am J Surg 2010; 199:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/39\">",
"      Balogh Z, McKinley BA, Cocanour CS, et al. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg 2003; 138:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/40\">",
"      Biffl WL, Moore EE, Burch JM, et al. Secondary abdominal compartment syndrome is a highly lethal event. Am J Surg 2001; 182:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/41\">",
"      O'Mara MS, Slater H, Goldfarb IW, Caushaj PF. A prospective, randomized evaluation of intra-abdominal pressures with crystalloid and colloid resuscitation in burn patients. J Trauma 2005; 58:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/42\">",
"      Patel NY, Cogbill TH, Kallies KJ, Mathiason MA. Temporary abdominal closure: long-term outcomes. J Trauma 2011; 70:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/43\">",
"      DiCocco JM, Magnotti LJ, Emmett KP, et al. Long-term follow-up of abdominal wall reconstruction after planned ventral hernia: a 15-year experience. J Am Coll Surg 2010; 210:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/44\">",
"      Sailes FC, Walls J, Guelig D, et al. Synthetic and biological mesh in component separation: a 10-year single institution review. Ann Plast Surg 2010; 64:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/45\">",
"      Hiles M, Record Ritchie RD, Altizer AM. Are biologic grafts effective for hernia repair?: a systematic review of the literature. Surg Innov 2009; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/46\">",
"      Diaz JJ Jr, Guy J, Berkes MB, et al. Acellular dermal allograft for ventral hernia repair in the compromised surgical field. Am Surg 2006; 72:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/47\">",
"      Tuveri M, Tuveri A, Nicol&ograve; E. Repair of large abdominal incisional hernia by reconstructing the midline and use of an onlay of biological material. Am J Surg 2011; 202:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/48\">",
"      Jin J, Rosen MJ, Blatnik J, et al. Use of acellular dermal matrix for complicated ventral hernia repair: does technique affect outcomes? J Am Coll Surg 2007; 205:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/49\">",
"      Scott BG, Welsh FJ, Pham HQ, et al. Early aggressive closure of the open abdomen. J Trauma 2006; 60:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/50\">",
"      Jernigan TW, Fabian TC, Croce MA, et al. Staged management of giant abdominal wall defects: acute and long-term results. Ann Surg 2003; 238:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/51\">",
"      Boele van Hensbroek P, Wind J, Dijkgraaf MG, et al. Temporary closure of the open abdomen: a systematic review on delayed primary fascial closure in patients with an open abdomen. World J Surg 2009; 33:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/52\">",
"      Roberts DJ, Zygun DA, Grendar J, et al. Negative-pressure wound therapy for critically ill adults with open abdominal wounds: a systematic review. J Trauma Acute Care Surg 2012; 73:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/53\">",
"      Diaz JJ Jr, Dutton WD, Ott MM, et al. Eastern Association for the Surgery of Trauma: a review of the management of the open abdomen--part 2 \"Management of the open abdomen\". J Trauma 2011; 71:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/54\">",
"      Pliakos I, Papavramidis TS, Mihalopoulos N, et al. Vacuum-assisted closure in severe abdominal sepsis with or without retention sutured sequential fascial closure: a clinical trial. Surgery 2010; 148:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/55\">",
"      Bee TK, Croce MA, Magnotti LJ, et al. Temporary abdominal closure techniques: a prospective randomized trial comparing polyglactin 910 mesh and vacuum-assisted closure. J Trauma 2008; 65:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/56\">",
"      Tieu BH, Cho SD, Luem N, et al. The use of the Wittmann Patch facilitates a high rate of fascial closure in severely injured trauma patients and critically ill emergency surgery patients. J Trauma 2008; 65:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/57\">",
"      Rasilainen SK, Mentula PJ, Lepp&auml;niemi AK. Vacuum and mesh-mediated fascial traction for primary closure of the open abdomen in critically ill surgical patients. Br J Surg 2012; 99:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/58\">",
"      Reimer MW, Yelle JD, Reitsma B, et al. Management of open abdominal wounds with a dynamic fascial closure system. Can J Surg 2008; 51:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/59\">",
"      Joglar F, Agosto E, Marrero D, et al. Dynamic retention suture closure: modified Bogot&aacute; bag approach. J Surg Res 2010; 162:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/60\">",
"      Koniaris LG, Hendrickson RJ, Drugas G, et al. Dynamic retention: a technique for closure of the complex abdomen in critically ill patients. Arch Surg 2001; 136:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1097/abstract/61\">",
"      Acosta S, Bjarnason T, Petersson U, et al. Multicentre prospective study of fascial closure rate after open abdomen with vacuum and mesh-mediated fascial traction. Br J Surg 2011; 98:735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15145 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1097=[""].join("\n");
var outline_f1_4_1097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H255249994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632146272\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632146279\">",
"      OPEN ABDOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255249462\">",
"      Etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67794622\">",
"      - Damage control surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67794629\">",
"      - Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67794601\">",
"      - Septic abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67794608\">",
"      - Refractory intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255249176\">",
"      Complications of open abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632146314\">",
"      TEMPORARY ABDOMINAL CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255251446\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255249609\">",
"      - Patch techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H632146335\">",
"      - Negative pressure wound systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41357434\">",
"      Towel-based",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41357441\">",
"      Sponge-based",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41357998\">",
"      - Silo techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41357891\">",
"      - Skin-only closures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170878938\">",
"      Adjunctive techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255251544\">",
"      Ostomy placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255250676\">",
"      CARE OF THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632146444\">",
"      ABDOMINAL CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255251569\">",
"      Fascial closure techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255250583\">",
"      - Primary fascial closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255250576\">",
"      - Functional closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255250177\">",
"      - Planned ventral hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170879412\">",
"      Rates of primary fascial closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255249994\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15145|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/37/15954\" title=\"figure 1\">",
"      Barker method of vacuum assisted temporary abdominal closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15145|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/21/33106\" title=\"picture 1\">",
"      Giant ventral hernia following open abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/61/31700\" title=\"picture 2\">",
"      Barker method of temporary abdominal closure in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/19/307\" title=\"picture 3\">",
"      Sponge based negative pressure wound system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/34/41519\" title=\"picture 4\">",
"      Bogota bag for managing open abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/29/41425\" title=\"picture 5\">",
"      Towel clamp closure of the abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/46/44783\" title=\"picture 6\">",
"      Vessel loop system for staged abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/26/13734\" title=\"picture 7\">",
"      Granulation bed on a chronically open abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15145|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4653\" title=\"table 1\">",
"      Richmond sedation scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=related_link\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32294?source=related_link\">",
"      Principles of component separation technique for complex abdominal wall defects and hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_4_1098="Bronchoprovocation testing";
var content_f1_4_1098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchoprovocation testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Charles G Irvin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/4/1098/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/4/1098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma has defied a precise definition acceptable to all, even though clinicians recognize that asthma will present with a constellation of signs and symptoms of intermittent dyspnea, cough, chest tightness, and wheezing. Part of the problem relates to the lack of specificity of these \"classic\" symptoms of asthma. Despite this variability, the following typical pathophysiologic features both characterize and assist in the diagnostic evaluation of the patient with asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversibility of airflow limitation. This is not always clinically demonstrable, as patients with mild disease often do not have airflow limitation at the time they are tested.",
"     </li>",
"     <li>",
"      Variable airflow limitation. As an example, patients with nocturnal asthma may have airflow limitation only after exposure to an asthma trigger or at night. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34472?source=see_link\">",
"       \"Nocturnal asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperresponsiveness to external triggers. \"Twitchy airways\" or airway hyperresponsiveness (AHR) is defined as an excessive response to an aerosolized provocation that elicits little or no response in a normal person.",
"     </li>",
"     <li>",
"      Inflammation of the airways is associated with and may underlie airway hyperresponsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several types of bronchoprovocation testing are available to assess airway responsiveness in specific patient situations, including pharmacologic challenge, exercise challenge, eucapnic voluntary hyperpnea, food additive challenge, and antigen challenge.",
"   </p>",
"   <p>",
"    The appropriate use of bronchoprovocation testing in patients with asthma or suspected of having asthma will be reviewed here. The pathogenesis and diagnosis of asthma and the role of bronchoprovocation testing in the diagnosis of occupational asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of airway responsiveness by bronchoprovocation testing is potentially useful for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to show airway hyperresponsiveness argues against the diagnosis of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      At any given point in time, airway hyperresponsiveness may be the sole objective evidence of airway dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Airway hyperresponsiveness is quantitatively associated with the presence and severity of disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Suppression of airway responsiveness is one of the qualities that can be used to assess new asthma therapies",
"     </li>",
"     <li>",
"      The occurrence of airway hyperresponsiveness in an asymptomatic person may help predict the future development of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The degree of airway hyperresponsiveness in a symptomatic person can have prognostic and potentially therapeutic implications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The periodicity of asthma exists in parallel with changes in the degree of airway hyperresponsiveness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first four reasons are the ones that are most important clinically; the other reasons are more applicable to research into asthma pathophysiology and the efficacy of asthma medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for bronchoprovocation testing include the accurate diagnosis of asthma in selected patients, assessment of the response to asthma therapy, and, less commonly, identification of triggers for cases involving environmental or occupational exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis of asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of asthma is often strongly suspected based upon the presence and pattern of typical symptoms that respond to specific therapy for asthma. The National Asthma Education and Prevention Program strongly encourages confirmation of the diagnosis with objective testing that shows reversibility of airflow limitation (eg, before and after bronchodilator, in response to ongoing therapy, or bronchoprovocation challenge) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients with typical intermittent asthma symptoms and normal baseline spirometry, a clear clinical response to empiric therapy may be adequate diagnostically. However, the cost and side effects of asthma treatment often warrant objective confirmation of the diagnosis with bronchoprovocation testing. Such testing is indicated in several clinical situations, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient who has symptoms consistent with asthma but normal pulmonary function test results and no response to a bronchodilator. This situation is commonly encountered in patients with mild or well-managed asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/10\">",
"       10",
"      </a>",
"      ]. Bronchoprovocation testing is the only way to make a positive and objective diagnosis of asthma in this setting.",
"     </li>",
"     <li>",
"      Patients who experience atypical symptoms of bronchospasm and therefore present with complaints not usually associated with asthma (eg, nocturnal awakening).",
"     </li>",
"     <li>",
"      Patients who present with symptoms that could result from asthma, but are ill-defined or nonspecific (eg, cough) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Asthma is one of the important causes of unexplained chronic cough; however, in the absence of bronchial hyperresponsiveness, a diagnosis other than asthma should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"       \"Evaluation of subacute and chronic cough in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are suspected of having occupational asthma, reactive airways dysfunction syndrome, or irritant-induced asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H11#H11\">",
"       \"Occupational asthma: Clinical features and diagnosis\", section on 'Nonspecific bronchoprovocation testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link&amp;anchor=H4798224#H4798224\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\", section on 'Nonspecific bronchoprovocation challenge'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For individuals who require screening test for asthma, such as scuba divers, military personnel, or other individuals in whom bronchospasm would pose an unacceptable hazard.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific bronchoprovocation challenge is sometimes used in clinical trials as a way to assess the response to a new therapy for asthma. This is particularly useful when evaluating patients with mild asthma whose only physiologic abnormality may be airway hyperresponsiveness and provides an additional endpoint other than symptoms alone. Rarely, serial bronchoprovocation testing is used to assess the response to avoidance of occupational exposures in occupational asthma, although this is predominantly for research purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Identification of specific asthma triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bronchoprovocation tests use a nonspecific agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) to assist in making the diagnosis of asthma. On rare occasions, it is necessary to test bronchoreactivity to specific food additives, occupational agents, or environmental antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"     \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link&amp;anchor=H8#H8\">",
"     \"Allergic and asthmatic reactions to food additives\", section on 'Asthmatic symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial challenge with nonspecific agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) is safe and easy to perform, as long as appropriate precautions are taken [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,10,14,15\">",
"     2,10,14,15",
"    </a>",
"    ]. American Thoracic Society guidelines regarding patient preparation and contraindications to methacholine challenge are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51312 \" href=\"UTD.htm?37/0/37900\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"     2",
"    </a>",
"    ]. Personnel performing the test should be able to recognize severe bronchospasm; a rapid acting beta agonist (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) should be immediately available either as a metered dose inhaler or nebulizer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Demonstration that the FEV",
"    <sub>",
"     1",
"    </sub>",
"    has returned to or exceeded baseline should be obtained before the patient leaves the pulmonary function laboratory. Resuscitation equipment should also be available.",
"   </p>",
"   <p>",
"    Patients with unstable cardiac disease or a myocardial infarction or stroke within the past three months are excluded from bronchoprovocation testing due to the physical exertion of the repeated measurements of spirometry (",
"    <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"     table 1",
"    </a>",
"    ). However, among adults without cardiac disease, the risk of adverse cardiac effects appears minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchoprovocation challenge should only be initiated in the absence of signs or symptoms of significant airflow obstruction. In patients with significant baseline impairment in the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), a bronchodilator reversibility study is usually indicated instead of bronchoprovocation (",
"    <a class=\"graphic graphic_algorithm graphicRef60462 \" href=\"UTD.htm?28/47/29439\">",
"     algorithm 1",
"    </a>",
"    ). Cutoff values below which bronchoprovocation testing is not routinely performed vary; guidelines suggest exclusion of patients with an FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;60 percent predicted, or an FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;1.5 liters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. We typically do not perform a bronchoprovocation challenge in a patient with an FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;70 percent predicted unless a physician is present.",
"   </p>",
"   <p>",
"    The safety of bronchoprovocation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    for patients with a baseline FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;60 percent predicted was evaluated in 88 patients who underwent methacholine challenge testing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/18\">",
"     18",
"    </a>",
"    ]. In this study, all but 4 of 88 patients returned to &gt;90 percent of their baseline FEV",
"    <sub>",
"     1",
"    </sub>",
"    following a single inhaled beta-agonist treatment, and the four nonresponders improved satisfactorily after a second treatment. No patients in this study experienced any adverse sequelae. However, bronchoprovocation testing in patients with this degree of baseline airflow obstruction should only be performed with great caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11359060\">",
"    <span class=\"h1\">",
"     ENSURING ADEQUATE SPIROMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reproducible spirometry is key to the performance of bronchoprovocation testing. Nose clips help to prevent leakage through the nasal passages and improve reliability. The testing requires multiple spirometric maneuvers, so it is important to explain to the patient the need for maximal and vigorous efforts and the importance of deep inhalation to full lung capacity for each maneuver. Depending on the protocol used, the exhalation time is 2 seconds (sometimes called an FEV",
"    <sub>",
"     1",
"    </sub>",
"    maneuver) or 6 seconds (most common). The shorter time may be used to decrease the respiratory effort and is often acceptable when vocal cord dysfunction is not a concern. When vocal cord dysfunction is a concern, a full flow volume loop is needed. Usually, two spirometric maneuvers are obtained at baseline and at each time point of the test. Details about proper coaching of patients during testing and assessing the adequacy of the flow-volume or FEV",
"    <sub>",
"     1",
"    </sub>",
"    tracing are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H5#H5\">",
"     \"Office spirometry\", section on 'Coaching the patient'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H6#H6\">",
"     \"Office spirometry\", section on 'Adequacy of test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the testing, the spirometric tracings are observed to make sure that the patient has fully inhaled to total lung capacity (TLC) prior to performing the expiratory maneuver. If the patient does not fully inhale to TLC, a decrease in FEV",
"    <sub>",
"     1",
"    </sub>",
"    can occur without bronchoconstriction and cause a false positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/19\">",
"     19",
"    </a>",
"    ]. Generally, forced vital capacity (FVC) is not used as an outcome measure for bronchoprovocation. Decreases in FVC usually reflect an inadequate inspiratory effort, incomplete exhalation, or an increase in residual volume (RV) due to airtrapping.",
"   </p>",
"   <p>",
"    For patients who have difficulty performing spirometry that meets acceptability standards, measures of airway resistance (eg, or specific airway conductance [sGaw]) may be obtained with the body plethysmograph and used as alternative end-points [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"     2",
"    </a>",
"    ]. Usually changes in sGaw mirror changes in FEV",
"    <sub>",
"     1",
"    </sub>",
"    , although sGaw changes are more variable. Thus, a larger percent change in sGaw (eg, 45 percent) is required for a positive test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic challenge procedures determine the dose-response characteristics of the airways to a provocative challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/20\">",
"     20",
"    </a>",
"    ]. When performing inhalational challenges, it is crucial that the solutions and nebulizer apparatus are prepared in a standardized fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the indication for testing, some or all of the patients&rsquo; medications may need to be stopped prior to testing (",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 2",
"    </a>",
"    ). Generally, inhaled glucocorticoids (ICS) are not stopped as it takes three weeks for the effect to wear off. However, a negative test while the patient is using ICS implies that the patient&rsquo;s current symptoms are not due to asthma, but does not rule out underlying asthma. To exclude airways hyperresponsiveness, the test would need to be repeated at least three weeks after discontinuation of ICS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623382\">",
"    <span class=\"h2\">",
"     Delivery of pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of provocative agents are administered via a nebulizer device (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , histamine, adenosine). The dose of a provocative agent that actually reaches the intrathoracic airways from an aerosol device can be difficult to quantify. In addition, the relative importance of the many factors (eg, nebulizer output, aerosol particle size, respiratory pattern) that influence aerosol delivery is largely unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to improve test standardization, the aerosol dose is reported as the concentration of the agonist",
"    <span class=\"nowrap\">",
"     (mg/mL)",
"    </span>",
"    in the nebulizer. Increasing concentrations of the provoking agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , histamine) are followed by spirometry at each step to generate a reproducible dose-response curve. In an attempt to standardize the delivered dosage, the agent is inhaled via a standardized aerosol delivery system (eg, an output of 0.13",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    while the subject performs a specific breathing maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The breathing maneuver typically uses a fixed inhalation scheme, for example, five vital capacity breaths with a breathhold, or two minutes of quiet (tidal volume) breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,14,23,25-27\">",
"     2,14,23,25-27",
"    </a>",
"    ]. The five vital capacity breath method is not equivalent to the two minutes of quiet breathing method for patients with mild hyperresponsiveness, probably due to the protective and bronchodilator effects of large vital capacity breaths [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, the quiet or tidal volume breathing method yields greater sensitivity. Alternatively, the five inhalations followed by breathhold can be modified to use a submaximal inhalation, approximately 50 or 60 percent below total lung capacity, followed by a breathhold [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/19,25,28\">",
"     19,25,28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial challenge tests are often classified as direct or indirect based on postulated mechanisms. Direct stimuli, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    and histamine, are thought to cause bronchoconstriction via direct stimulation of airway smooth muscle receptors, whereas indirect stimuli (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , adenosine monophosphate, eucapnic hyperventilation) cause bronchoconstriction through one or more intermediate pathways, typically involving release of inflammatory mediators (eg, prostaglandin D2, leukotriene E4) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/29\">",
"     29",
"    </a>",
"    ]. However, direct stimuli such as histamine or methacholine also affect other cells besides smooth muscle, such as nerves and mucous containing cells.",
"   </p>",
"   <p>",
"    Histamine has been used in research studies of bronchial challenge, but is much less commonly employed clinically than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , due to its frequent induction of flushing and headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, histamine is not commercially available for this use. Methacholine and histamine challenge appear to give equivalent results in selected groups of asthmatic subjects, but in theory, they are not equivalent challenges since they stimulate different receptors and histamine is known to activate airway neural reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/26,31\">",
"     26,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other compounds that have been used or advocated for use in bronchoprovocation challenge include bradykinin, adenosine monophosphate (AMP), hypertonic saline, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/24,32-45\">",
"     24,32-45",
"    </a>",
"    ]. As an example, one study comparing serial AMP and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge testing in 120 asthmatics found that AMP was more closely associated with other markers of airway inflammation, and more sensitive to subtle changes in airway responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/35\">",
"     35",
"    </a>",
"    ]. Administration of these compounds appears to distinguish patients with asthma from normal subjects; however, clinical experience is more limited than with methacholine or histamine. In addition, normative data on the expected effect of inhaled AMP in normal control subjects is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, it appears that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    is more sensitive for airway hyperresponsiveness, but less specific compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/24,47,48\">",
"     24,47,48",
"    </a>",
"    ]. The optimal roles of methacholine and mannitol challenge in the assessment of airway hyperresponsiveness for clinical purposes remain unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Methacholine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     Methacholine",
"    </a>",
"    , a derivative of acetylcholine, is the agent most commonly used for bronchoprovocation and is an acceptable form of bronchoprovocation for assessing asthma in Olympic athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/49\">",
"     49",
"    </a>",
"    ]. Bronchoconstriction due to methacholine is of longer duration than that due to acetylcholine, thus facilitating measurement of the response. The American Thoracic Society and the European Respiratory Society have both published guidelines regarding methacholine challenge testing procedures (",
"    <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef60462 \" href=\"UTD.htm?28/47/29439\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    A series of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    chloride solutions are prepared, ranging from approximately 0.03",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (the most dilute) to 16",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (the most concentrated). As shown in the table, these solutions are usually prepared in two-fold dilutions (",
"    <a class=\"graphic graphic_table graphicRef51312 \" href=\"UTD.htm?37/0/37900\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After baseline spirometry that meets criteria noted elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"     2",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H6#H6\">",
"     \"Office spirometry\", section on 'Adequacy of test'",
"    </a>",
"    ), either diluent (most common) or the most dilute concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    is administered by nebulizer, using either a tidal breathing or five breath dosimeter method. (See",
"    <a class=\"local\" href=\"#H5623382\">",
"     'Delivery of pharmacologic agents'",
"    </a>",
"    above.) After inhalation of the aerosol by one of these methods, the FEV",
"    <sub>",
"     1",
"    </sub>",
"    is measured at 30 and 90 seconds with careful coaching of the subject to obtain an acceptable quality FEV",
"    <sub>",
"     1",
"    </sub>",
"    . Each time two maneuvers are performed; if FEV",
"    <sub>",
"     1",
"    </sub>",
"    is the only outcome being measured, it is acceptable to shorten the expiratory time to about 2 seconds (from the usual 6 seconds), unless there is a suspicion of vocal cord dysfunction in which case a full vital capacity maneuver with inspiratory and expiratory phases is performed.",
"   </p>",
"   <p>",
"    The concentration is sequentially increased one concentration step at a time (",
"    <a class=\"graphic graphic_table graphicRef51312 \" href=\"UTD.htm?37/0/37900\">",
"     table 3",
"    </a>",
"    ), until a decrease in FEV",
"    <sub>",
"     1",
"    </sub>",
"    greater than 20 percent or a 35 or 40 percent decrease in specific airways conductance (SGaw) is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,14,22\">",
"     2,14,22",
"    </a>",
"    ]. Typically, when there is a positive test, the FEV",
"    <sub>",
"     1",
"    </sub>",
"    decreases more than 20 percent, so the dose of the inhaled antagonist that would provoke a 20 percent drop in FEV",
"    <sub>",
"     1",
"    </sub>",
"    is determined by interpolation. This is referred to as the provocative concentration or PC20. Generally, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    PC20 of 8",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (&lt;4",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    for SGaw) or less is considered a positive test. A PC20 greater than 16",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    is considered a negative test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22416491\">",
"    <span class=\"h2\">",
"     Mannitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    inhalation is thought to cause bronchoconstriction by increasing the osmolarity of the airway surface, resulting in release of mast cell mediators. The mast cell mediators (eg, prostaglandin D2, leukotriene E4) in turn cause bronchoconstriction. Mannitol has been approved by the United States Food and Drug Administration (FDA) for bronchoprovocation challenge and is widely available in other countries. The guidelines published by the American Thoracic Society and the European Respiratory Society for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge testing procedures are also appropriate for mannitol bronchoprovocation (",
"    <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    is available as a dry powder in capsules containing graduated doses that are administered via a dry powder inhaler (Aridol) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/43\">",
"     43",
"    </a>",
"    ]. Due to the availability of premeasured doses, mannitol inhalation challenge may prove to be more convenient than challenges with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , exercise, or isocapnic hyperventilation.",
"   </p>",
"   <p>",
"    For the bronchoprovocation procedure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    dry powder is rapidly inhaled in progressively increasing doses (0, 5, 10, 20, 40, 80, 160, 160, 160 mg). The forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) is measured at baseline and repeated at 1 minute after each dose; the best of two repeatable values is used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/25,42\">",
"     25,42",
"    </a>",
"    ]. If the FEV",
"    <sub>",
"     1",
"    </sub>",
"    decreases by 10 percent after a dose then that dose is repeated. A 15 percent fall in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at a total cumulative dose of &le;635 mg (known as the provocative dose or PD 15) is considered a positive response.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    challenge appears to be safe; among 592 subjects with and without asthma who underwent mannitol bronchoprovocation, no serious adverse events were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/41\">",
"     41",
"    </a>",
"    ]. However, cough is a common side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623764\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To interpret a bronchoprovocation challenge test, a graph is drawn plotting the fall in the outcome indicator (eg, forced expiratory volume in one second [FEV",
"    <sub>",
"     1",
"    </sub>",
"    ]) versus the concentration of provocational agent (",
"    <a class=\"graphic graphic_figure graphicRef82365 \" href=\"UTD.htm?41/63/43005\">",
"     figure 1",
"    </a>",
"    ). The effective concentration that would have resulted in a given change in the outcome indicator is determined by interpolation. This dose of the provocative agent (eg, provocative concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    for a 20 percent fall in the FEV",
"    <sub>",
"     1",
"    </sub>",
"    or provocative dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    for a 15 percent fall in FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), is used to interpret the test. Through experience with each agent, concentrations in the normal, asthmatic, and indeterminate ranges have been ascertained. As noted above, the PC20-FEV",
"    <sub>",
"     1",
"    </sub>",
"    for methacholine in patients with asthma is usually 8",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or less.",
"   </p>",
"   <p>",
"    It is difficult to calculate the exact sensitivity of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge for the diagnosis of asthma, as a gold standard for diagnosing asthma does not exist. On the other hand, for a cut-point of 8 to 16",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    using a non-deep inhalation method, the sensitivity is felt to approach 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/24,50,51\">",
"     24,50,51",
"    </a>",
"    ]. The positive predictive value is more limited (estimated around 50 percent for a cut-point of",
"    <span class=\"nowrap\">",
"     8mg/mL),",
"    </span>",
"    as false positive results may be seen in patients with allergic rhinitis, cystic fibrosis, heart failure, COPD, and bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. Thus, the negative predictive value is the most useful aspect of methacholine challenge. (See",
"    <a class=\"local\" href=\"#H5623778\">",
"     'Asymptomatic patient, positive test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623771\">",
"    <span class=\"h2\">",
"     Difficult interpretations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of bronchoprovocation testing can be difficult to interpret when a patient with a positive test has no symptoms of asthma, or when a patient with a negative result has symptoms suggestive of asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623778\">",
"    <span class=\"h3\">",
"     Asymptomatic patient, positive test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies indicate that approximately 1 to 7 percent of the population have reactive airways (up to 26 percent if smokers are included) but are otherwise normal or asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. These individuals may represent the \"tail\" of a normal bell-shaped population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/52\">",
"     52",
"    </a>",
"    ], or alternatively they may have asthma but do not perceive any symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. The latter possibility is supported by the observations that poor perception of airflow limitation occurs in some asthmatics who are at risk for unexpected exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/11\">",
"     11",
"    </a>",
"    ], and subjects with \"laboratory asthma\" may in fact subsequently develop a clinical diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/3,55\">",
"     3,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623785\">",
"    <span class=\"h3\">",
"     History suggestive of asthma, negative test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies report that airway hyperresponsiveness, as measured by a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    PC20, is consistent and reproducible in asthmatics; however, these studies largely evaluated patients with stable asthma. The following clinical settings are examples of situations in which a patient may report a convincing history of asthma but have a negative challenge.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inhalation of an antigen with a subsequent late asthmatic response, as seen in certain occupational exposures. After resolution of the late asthmatic response, many patients are hyperresponsive for weeks, but gradually return to normal [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/1\">",
"       1",
"      </a>",
"      ]. On the other hand, some patients show a rapid resolution of hyperresponsiveness. As a result, it is very important to relate the PC20 result to the presence or absence of current respiratory symptoms and exposures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H11#H11\">",
"       \"Occupational asthma: Clinical features and diagnosis\", section on 'Nonspecific bronchoprovocation testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paradoxical vocal cord motion (also known as vocal cord dysfunction) may result in symptoms suggestive of asthma but a negative challenge test result, if the only endpoint is the change in FEV",
"      <sub>",
"       1",
"      </sub>",
"      . This condition is often detected by careful inspection of the inspiratory flow-volume relationship. Patients may have predominantly inspiratory or expiratory vocal cord dysfunction, with corresponding inspiratory or expiratory abnormalities on the flow-volume loop (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7554031\">",
"       'History suggestive of asthma, atypical spirometry pattern'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"       \"Flow-volume loops\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central airway obstruction by a tumor, polyp, or foreign body can also mimic asthma symptomatically, but results in a negative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      challenge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=see_link\">",
"       \"Airway foreign bodies in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7554031\">",
"    <span class=\"h3\">",
"     History suggestive of asthma, atypical spirometry pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway responses to various challenge procedures are common and can lead to confusing results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/56\">",
"     56",
"    </a>",
"    ]. As an example, patients with vocal cord dysfunction may develop flattening of the inspiratory portion of the flow volume loop in response to pharmacologic bronchoprovocation challenge. Fortunately, this can usually be detected if full inspiratory as well as expiratory flow-volume loops are performed and inspected, although direct laryngoscopy may be required to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXERCISE CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is thought to be a trigger for bronchoconstriction in virtually all patients with hyperreactive airways and may be the only trigger for a subset of patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/31\">",
"     31",
"    </a>",
"    ]. The identification of exercise-induced bronchoconstriction (EIB) and the documentation of its successful treatment are important and practical considerations for children and active adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/57\">",
"     57",
"    </a>",
"    ]. Graded exercise in a monitored setting provides a useful challenge test for the evaluation and management of EIB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchodilator therapy and cromolyn are withheld prior to testing (",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 2",
"    </a>",
"    ), as these can block a bronchospastic response to exercise testing, causing a false negative result. After vigorous exercise, some patients have a refractory period during which EIB is suppressed, so vigorous exercise should also be avoided the day of the testing.",
"   </p>",
"   <p>",
"    The presence of EIB is determined using the following general protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,58\">",
"     2,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline spirometry values are determined by obtaining two reproducible maneuvers within 3 percent of each other; the best maneuver is used to calculate post exercise falls in FEV",
"      <sub>",
"       1",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/58\">",
"       58",
"      </a>",
"      ]. If vocal cord dysfunction is suspected, full inspiratory and expiratory maneuvers are performed before and after exercise.",
"     </li>",
"     <li>",
"      Monitoring during the test generally includes a continuous electrocardiogram, blood pressure, pulse oximetry, and minute ventilation.",
"     </li>",
"     <li>",
"      Airway drying caused by the increased minute ventilation during exercise is thought to be the stimulus for exercise-induced bronchoconstriction, so careful control of the temperature and humidity of the inhaled air are needed to ensure test reliability [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. This is typically achieved by having the patient breathe dry, medical grade air (&lt;5 mg",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      air) administered via a gas cylinder with a reservoir bag (Douglas bag apparatus) and a one-way mouth valve. Nose clips should be worn during the test to avoid entrainment of ambient air [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The preferred modes of exercise are either a motor-driven treadmill or the electromagnetically braked cycle ergometer.",
"     </li>",
"     <li>",
"      The exercise protocol is selected to allow the patient to achieve 80 to 90 percent of predicted maximum heart rate (estimate at 220 minus age in years) in the first two minutes of exercise and maintain it for the remaining eight minutes of the test. Patients should reach 40 to 60 percent of their predicted maximum voluntary ventilation (MVV). The predicted MVV can be calculated by taking the pretest FEV",
"      <sub>",
"       1",
"      </sub>",
"      and multiplying by a factor between 35 and 40; for convenience 40 is widely used [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spirometry is performed prior to exercise, and at 5, 10, 15, 20, and 30 minutes thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"       2",
"      </a>",
"      ]. It is important to assess lung function serially after exercise, as bronchoconstriction usually occurs 10 to 15 minutes after the end of exercise.",
"     </li>",
"     <li>",
"      A test is generally considered positive if the forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) decreases by 10 percent, although a fall of 15 percent is more diagnostic.",
"     </li>",
"     <li>",
"      Asthma symptoms and bronchoconstriction provoked by the testing are treated with inhalation of a short-acting beta agonist (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Precautions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An inadequate exercise stimulus that fails to raise the minute ventilation sufficiently is the most common problem with this test, and may result in a false negative result. If this occurs, other provocative maneuvers that may elicit bronchospasm include free running, the addition of cold air, or eucapnic voluntary hyperpnea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/59,62,63\">",
"     59,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a positive exercise challenge test, the efficacy of preventative medications (eg, short-acting beta agonist, antileukotriene agent) can be assessed by repeating the test on medication, although this is not necessary in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5620471\">",
"    <span class=\"h1\">",
"     EUCAPNIC VOLUNTARY HYPERPNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eucapnic voluntary hyperpnea (EVH, also known as isocapnic voluntary hyperventilation) is another type of challenge for assessing airway hyperresponsiveness (AHR). It is thought that dry air hyperventilation causes drying and hyperosmolarity of the airway surface (similar to the effect of exercise), resulting in release of inflammatory mediators from inflammatory cells such as mast cells (similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    inhalation) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/58\">",
"     58",
"    </a>",
"    ]. EVH is one of the recommended challenge tests for identifying EIB in Olympic athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/49,64,65\">",
"     49,64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For the procedure, baseline spirometry is performed twice to obtain two values for FEV",
"    <sub>",
"     1",
"    </sub>",
"    that are reproducible; the best value for FEV",
"    <sub>",
"     1",
"    </sub>",
"    is used to calculate the post challenge changes. The patient wears nose clips and orally inhales a mixture of dry hypercapnic air (4.5 to 5 percent CO",
"    <sub>",
"     2",
"    </sub>",
"    , 21 percent O",
"    <sub>",
"     2",
"    </sub>",
"    , balanced N",
"    <sub>",
"     2",
"    </sub>",
"    ). The hypercapnic air ensures eucapnia during the test, as hypocapnia can cause bronchoconstriction. It is not necessary to chill the inspired air as it is believed that the water content and not the air temperature is the essential feature that leads to bronchoconstriction in patients with airway hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/58,66\">",
"     58,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient is instructed to breathe at a predetermined rate of 60 to 85 percent of maximum voluntary ventilation (MVV) for six minutes. For the test, 85 percent of MVV is achieved by having the patient breathe 30 times a minute at a tidal volume approximately equal to the baseline FEV",
"    <sub>",
"     1",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/65\">",
"     65",
"    </a>",
"    ]. Two reproducible postexercise spirometry maneuvers are performed at each time point of 5, 10, and 15 minutes after the completion of the challenge. A test is generally considered positive if the FEV",
"    <sub>",
"     1",
"    </sub>",
"    decreases by 10 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/49,65\">",
"     49,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26846610\">",
"    <span class=\"h1\">",
"     ANTIGEN CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accurate identification of a specific inhaled allergen by antigenic challenge is largely a research tool for investigation of mechanisms of asthma, the efficacy of new therapeutic agents, and suspected occupational allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/2,67\">",
"     2,67",
"    </a>",
"    ]. Allergen inhalation challenge is a specialized procedure and should not be undertaken by individuals unfamiliar with the technique. Some patients may have a severe response requiring hospitalization.",
"   </p>",
"   <p>",
"    Bronchoprovocation tests with specific occupational agents should only be performed in specialized centers, and may require over 24 hours of monitoring following the challenge procedure to detect and, if necessary, treat a late asthmatic response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"     \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26846649\">",
"    <span class=\"h1\">",
"     ASPIRIN CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and reactions to ingestion of aspirin or other cyclo-oxygenase-1 inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 4",
"    </a>",
"    ). The reactions to aspirin and NSAIDs typically begin 30 minutes after ingestion and involve marked nasal congestion and bronchospasm. Oral aspirin challenge is performed in patients with suspected AERD who have a medical indication for aspirin or NSAID therapy at a time when their asthma is under good control.",
"   </p>",
"   <p>",
"    The technique for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge requires safeguards such as premedication with a leukotriene modifying agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ), ensuring that the patient&rsquo;s asthma is well-controlled at the time of challenge, performing the challenge in a medically-monitored setting, and obtaining intravenous access prior to the challenge. A detailed description of the challenge procedure is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FOOD ADDITIVE CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another form of bronchoprovocation testing involves challenge with food additives, which can be useful in patients who describe food intolerances. Sulfites (found in food preservatives as an antioxidant) and tartrazine (found in orange food color) are the food additives most commonly studied [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. Oral ingestion of sulfites may result in bronchoconstriction due to the inhalation of sulfur dioxide (SO",
"    <sub>",
"     2",
"    </sub>",
"    ), which is produced by the acidification of metabisulfite in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interpretation of the results of food additive challenge is difficult because one can only estimate the amount of dietary exposure from these preservatives. Nevertheless, since the response to these agents can be quite severe, a negative test result can be clinically important, because it will free patients from concern about the ingestion of these compounds.",
"   </p>",
"   <p>",
"    A bronchospastic response to a food additive is a relatively uncommon problem in asthma, since less than 5 percent of the asthmatic population is thought to be sensitive to these compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?1/4/1098/abstract/74\">",
"     74",
"    </a>",
"    ]. Testing, which should be done in specialized laboratories, involves blinded challenge with the agent in question and serial monitoring of lung function.",
"   </p>",
"   <p>",
"    Oral food challenges for the diagnosis of food allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link&amp;anchor=H13#H13\">",
"     \"Oral food challenges for diagnosis and management of food allergies\", section on 'Performance of an OFC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several types of bronchoprovocation testing are available to assess airway responsiveness in specific patient situations, including pharmacologic challenge, exercise challenge, eucapnic voluntary hyperpnea, food additive challenge, and antigen challenge. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonspecific bronchoprovocation testing (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      ) is indicated when the diagnosis of asthma is in question (eg, symptoms are atypical, baseline spirometry is normal), when a patient is suspected of having occupational asthma, reactive airways dysfunction syndrome (RADS), or irritant-induced asthma, and when a screening test for asthma is required for scuba divers, military personnel, or other individuals in whom bronchospasm would pose an unacceptable hazard. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contraindications to bronchoprovocation challenge and a list of medications that need to be discontinued prior to testing are listed in the tables (",
"      <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacologic challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       Methacholine",
"      </a>",
"      inhalation challenge is the most common type of pharmacologic challenge. Patients breathe progressively stronger doses of methacholine according to a protocol (",
"      <a class=\"graphic graphic_algorithm graphicRef60462 \" href=\"UTD.htm?28/47/29439\">",
"       algorithm 1",
"      </a>",
"      ). The dose of methacholine that provokes a 20 percent drop in FEV",
"      <sub>",
"       1",
"      </sub>",
"      is referred to as the PC20. Generally, a PC20 of 8",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      methacholine or less is considered a positive test. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacologic challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      inhalation challenge is mediated by release of bronchoconstrictive mediators. The contraindications and a list of medications that need to be discontinued are the same as for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"       table 2",
"      </a>",
"      ). Mannitol challenge is performed by oral inhalation of a dry powder at progressively increasing doses. A 15 percent fall in FEV",
"      <sub>",
"       1",
"      </sub>",
"      at a total cumulative dose of &le;635 mg (known as the provocative dose or PD 15) is considered a positive response. (See",
"      <a class=\"local\" href=\"#H22416491\">",
"       'Mannitol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise testing and eucapnic voluntary hyperpnea (EVH) are forms of bronchoprovocation used for patients with symptoms suggestive of asthma during exercise, but with normal spirometry at rest. A small portion of patients with exercise-induced bronchoconstriction have negative tests to pharmacologic bronchoprovocation tests, so exercise testing and EVH are needed for diagnostic purposes and sometimes to assess the response to therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Exercise challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For formal exercise challenge tests, the patient is exercised on a treadmill or cycle ergometer to 80 to 90 percent of predicted maximum heart rate (220 minus age in years) for six to eight minutes. Patients should reach 40 to 60 percent of their predicted maximum voluntary ventilation. Spirometry is performed prior to exercise, and at 5, 10, 15, 20, and 30 minutes thereafter. A test is generally considered positive if the FEV",
"      <sub>",
"       1",
"      </sub>",
"      decreases by 10 percent, although a fall of 15 percent is more diagnostic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Exercise challenge'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"       \"Exercise-induced bronchoconstriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For eucapnic voluntary hyperpnea testing, the patient breathes dry hypercapnic air for six minutes at a respiratory rate and volume of 30 times the FEV",
"      <sub>",
"       1",
"      </sub>",
"      . Spirometry is performed prior to the test, and at 5, 10, and 15 minutes after completion. A test is generally considered positive if the FEV",
"      <sub>",
"       1",
"      </sub>",
"      decreases by 10 percent or more. (See",
"      <a class=\"local\" href=\"#H5620471\">",
"       'Eucapnic voluntary hyperpnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhalation of nebulized allergens (eg, dust mite, animal danders, occupational agents) carries greater risk and is reserved for research purposes, occupational asthma, and rare clinical situations. (See",
"      <a class=\"local\" href=\"#H26846610\">",
"       'Antigen challenge'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"       \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      The indications, contraindications, and technique of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge in patients suspected of having aspirin-exacerbated respiratory disease are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"       \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, oral challenges with food additives (eg, sodium metabisulfite) are performed in specialized laboratories for the evaluation of suspected intolerance. Oral ingestion of sulfites is thought to result in bronchoconstriction due to the inhalation of sulfur dioxide (SO",
"      <sub>",
"       2",
"      </sub>",
"      ), which is produced by the acidification of metabisulfite in the stomach. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Food additive challenge'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link&amp;anchor=H8#H8\">",
"       \"Allergic and asthmatic reactions to food additives\", section on 'Asthmatic symptoms'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/1\">",
"      Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 1977; 7:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/2\">",
"      Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/3\">",
"      Laprise C, Laviolette M, Boutet M, Boulet LP. Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling. Eur Respir J 1999; 14:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/4\">",
"      Weiss ST, Van Natta ML, Zeiger RS. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med 2000; 162:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/5\">",
"      Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax 1981; 36:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/6\">",
"      Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/7\">",
"      Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001; 18:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/8\">",
"      Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128:508.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/10\">",
"      Goldstein MF, Pacana SM, Dvorin DJ, Dunsky EH. Retrospective analyses of methacholine inhalation challenges. Chest 1994; 105:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/11\">",
"      Rubinfeld AR, Pain MC. Perception of asthma. Lancet 1976; 1:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/12\">",
"      Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/13\">",
"      Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/14\">",
"      Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/15\">",
"      Covar RA, Colvin R, Shapiro G, Strunk R. Safety of methacholine challenges in a multicenter pediatric asthma study. J Allergy Clin Immunol 2006; 117:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/16\">",
"      Pratter MR, Bartter TC, Dubois J. Bronchodilator reversal of bronchospasm and symptoms incurred during methacholine bronchoprovocation challenge. Documentation of safety and time course. Chest 1993; 104:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/17\">",
"      Malerba M, Radaeli A, Politi A, et al. Cardiac arrhythmia monitoring during bronchial provocation test with methacholine. Chest 2003; 124:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/18\">",
"      Martin RJ, Wanger JS, Irvin CG, et al. Methacholine challenge testing: safety of low starting FEV1. Asthma Clinical Research Network (ACRN). Chest 1997; 112:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/19\">",
"      Cockcroft DW. Methacholine challenge methods. Chest 2008; 134:678.",
"     </a>",
"    </li>",
"    <li>",
"     National asthma education program. Expert Panel Report: Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, Publication No. 91-3042, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/21\">",
"      Ryan G, Dolovich MB, Obminski G, et al. Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation. J Allergy Clin Immunol 1981; 67:156.",
"     </a>",
"    </li>",
"    <li>",
"     Dolovich, MB. Technical factors influencing response to challenge aerosols. In: Airway Responsiveness: Measurement and Interpretation, Hargreave, FE, Woolcock, AJ (Eds), Astra Pharmaceuticals, Mississauga, Ontario 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/23\">",
"      Ryan G, Dolovich MB, Roberts RS, et al. Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared. Am Rev Respir Dis 1981; 123:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/24\">",
"      Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138:18S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/25\">",
"      Cockcroft DW, Davis BE. The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. J Allergy Clin Immunol 2006; 117:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/26\">",
"      Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981; 68:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/27\">",
"      Prieto L, Lopez V, Llusar R, et al. Differences in the response to methacholine between the tidal breathing and dosimeter methods: influence of the dose of bronchoconstrictor agent delivered to the mouth. Chest 2008; 134:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/28\">",
"      Todd DC, Davis BE, Hurst TS, Cockcroft DW. Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations. J Allergy Clin Immunol 2004; 114:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/29\">",
"      Anderson SD. Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/30\">",
"      Toelle BG, Li J, Dalton M, Devadason SG. Subject discomfort associated with the histamine challenge in a population study. Respir Med 2002; 96:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/31\">",
"      Chatham M, Bleecker ER, Smith PL, et al. A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects. Am Rev Respir Dis 1982; 126:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/32\">",
"      Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987; 135:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/33\">",
"      Holgate ST, Mann JS, Cushley MJ. Adenosine as a bronchoconstrictor mediator in asthma and its antagonism by methylxanthines. J Allergy Clin Immunol 1984; 74:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/34\">",
"      Anderson SD. Exercise-induced asthma and the use of hypertonic saline aerosol as a bronchial challenge. Respirology 1996; 1:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/35\">",
"      van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/36\">",
"      Currie GP, Haggart K, Brannan JD, et al. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/37\">",
"      Prieto L, Bruno L, Guti&eacute;rrez V, et al. Airway responsiveness to adenosine 5'-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. Chest 2003; 124:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/38\">",
"      Koskela HO, Hyv&auml;rinen L, Brannan JD, et al. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest 2003; 124:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/39\">",
"      Koskela HO, Hyv&auml;rinen L, Brannan JD, et al. Responsiveness to three bronchial provocation tests in patients with asthma. Chest 2003; 124:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/40\">",
"      Koskela HO, Hyv&auml;rinen L, Brannan JD, et al. Coughing during mannitol challenge is associated with asthma. Chest 2004; 125:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/41\">",
"      Brannan JD, Anderson SD, Perry CP, et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005; 6:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/42\">",
"      Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study. J Allergy Clin Immunol 2009; 124:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/43\">",
"      Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 10:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/44\">",
"      O'Byrne PM, Gauvreau GM, Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009; 39:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/45\">",
"      Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin Exp Allergy 2008; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/46\">",
"      Ramsdell JW. Adenosine airways responsiveness: what does it mean? Chest 2003; 123:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/47\">",
"      Andregnette-Roscigno V, Fern&aacute;ndez-Nieto M, Del Potro MG, et al. Methacholine is more sensitive than mannitol for evaluation of bronchial hyperresponsiveness in children with asthma. J Allergy Clin Immunol 2010; 126:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/48\">",
"      Carlsen KH, Anderson SD, Bjermer L, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 2008; 63:387.",
"     </a>",
"    </li>",
"    <li>",
"     Beta2 adrenoreceptor agonists and the Olympic games in Beijing file://www.olympic.org/Documents/Reports/EN/en_report_1302.pdf (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/50\">",
"      Goldstein MF, Veza BA, Dunsky EH, et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/51\">",
"      Cockcroft DW, Murdock KY, Berscheid BA, Gore BP. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol 1992; 89:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/52\">",
"      Cockcroft DW, Berscheid BA, Murdock KY. Unimodal distribution of bronchial responsiveness to inhaled histamine in a random human population. Chest 1983; 83:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/53\">",
"      Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980; 122:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/54\">",
"      Paoletti P, Carrozzi L, Viegi G, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am J Respir Crit Care Med 1995; 151:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/55\">",
"      Hopp RJ, Townley RG, Biven RE, et al. The presence of airway reactivity before the development of asthma. Am Rev Respir Dis 1990; 141:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/56\">",
"      Christopher KL, Wood RP 2nd, Eckert RC, et al. Vocal-cord dysfunction presenting as asthma. N Engl J Med 1983; 308:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/57\">",
"      Eggleston PA, Rosenthal RR, Anderson SA, et al. Guidelines for the methodology of exercise challenge testing of asthmatics. Study Group on Exercise Challenge, Bronchoprovocation Committee, American Academy of Allergy. J Allergy Clin Immunol 1979; 64:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/58\">",
"      Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. J Allergy Clin Immunol 2008; 122:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/59\">",
"      Anderson SD. Issues in exercise-induced asthma. J Allergy Clin Immunol 1985; 76:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/60\">",
"      Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J 2003; 21:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/61\">",
"      American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/62\">",
"      Chen WY, Horton DJ. Heat and water loss from the airways and exercise-induced asthma. Respiration 1977; 34:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/63\">",
"      McFadden ER Jr. Exercise and asthma. N Engl J Med 1987; 317:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/64\">",
"      Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006; 117:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/65\">",
"      Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest 2004; 125:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/66\">",
"      Evans TM, Rundell KW, Beck KC, et al. Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 2005; 128:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/67\">",
"      Boulet LP, Gauvreau G, Boulay ME, et al. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007; 62:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/68\">",
"      Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/69\">",
"      Simon RA. Sulfite challenge for the diagnosis of sensitivity. Allergy Proc 1989; 10:357.",
"     </a>",
"    </li>",
"    <li>",
"     Spector SL, Farr RS. National Jewish Hospital experience with aspirin, tartrazine and analgesic oral challenge. In: Provocative challenge procedures: Bronchial, oral nasal and exercise, Spector SL (Ed), CRC Press, Boca Raton 1983. Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/71\">",
"      Vally H, Carr A, El-Saleh J, Thompson P. Wine-induced asthma: a placebo-controlled assessment of its pathogenesis. J Allergy Clin Immunol 1999; 103:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/72\">",
"      Delohery J, Simmul R, Castle WD, Allen DH. The relationship of inhaled sulfur dioxide reactivity to ingested metabisulfite sensitivity in patients with asthma. Am Rev Respir Dis 1984; 130:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/4/1098/abstract/73\">",
"      Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev Allergy 1990; 8:159.",
"     </a>",
"    </li>",
"    <li>",
"     Farr, RS. Asthma induced by aspirin and metabisulfites. In: Current therapy of respiratory disease, Cherniack, RM (Eds), BC Decker, Philadelphia 1984.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 525 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1098=[""].join("\n");
var outline_f1_4_1098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis of asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Identification of specific asthma triggers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11359060\">",
"      ENSURING ADEQUATE SPIROMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOLOGIC CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623382\">",
"      Delivery of pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methacholine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22416491\">",
"      Mannitol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623764\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623771\">",
"      Difficult interpretations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623778\">",
"      - Asymptomatic patient, positive test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623785\">",
"      - History suggestive of asthma, negative test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7554031\">",
"      - History suggestive of asthma, atypical spirometry pattern",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXERCISE CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5620471\">",
"      EUCAPNIC VOLUNTARY HYPERPNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26846610\">",
"      ANTIGEN CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26846649\">",
"      ASPIRIN CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FOOD ADDITIVE CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/525|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/47/29439\" title=\"algorithm 1\">",
"      MCT flowchart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/525|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/43005\" title=\"figure 1\">",
"      Bronchoprovocation test asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 2\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/61/24539\" title=\"table 1\">",
"      Contraindications to bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/29/7645\" title=\"table 2\">",
"      Medications and bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/0/37900\" title=\"table 3\">",
"      Methacholine preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 4\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34472?source=related_link\">",
"      Nocturnal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_4_1099="Histologic differential of microcystic adnexal carcinoma";
var content_f1_4_1099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic differential diagnosis of microcystic adnexal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Morpheaform basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desmoplastic squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desmoplastic trichoepithelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eccrine carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastatic breast carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1099=[""].join("\n");
var outline_f1_4_1099=null;
var title_f1_4_1100="CMML criteria WHO";
var content_f1_4_1100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO criteria for the diagnosis of chronic myelomonocytic leukemia (CMML)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Persistent peripheral blood monocytosis; absolute monocyte count &gt;1000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Philadelphia chromosome or BCR/ABL fusion gene absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;20 percent myeloblasts + monoblasts + promonocytes in peripheral blood or bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dysplastic changes in one or more myeloid lineages. If myelodysplasia is absent or minimal, the diagnosis of CMML can be made if the above three criteria are met",
"        <strong>",
"         and:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        An acquired clonal cytogenetic abnormality is present in bone marrow cells,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Persistent monocytosis for &ge;3 months and all other causes of monocytosis have been excluded",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CMML-1:",
"        </strong>",
"        Blasts &lt;5 percent in peripheral blood and &lt;10 percent in bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CMML-2:",
"        </strong>",
"        Blasts 5 to 19 percent in peripheral blood or 10 to 19 percent in bone marrow,",
"        <strong>",
"         or",
"        </strong>",
"        Auer rods are present and blasts are &lt;20 percent in peripheral blood or bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CMML-1 or CMML-2 with eosinophilia:",
"        </strong>",
"        Above criteria for CMML-1",
"        <strong>",
"         or",
"        </strong>",
"        CMML-2 present along with peripheral blood absolute eosinophil count &gt;1500/ microL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Vardiman JW, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2001. p.49. Permission granted from Harris NL and Vardiman JW.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1100=[""].join("\n");
var outline_f1_4_1100=null;
var title_f1_4_1101="Clinical classification of panniculitis";
var content_f1_4_1101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical classification of panniculitis based upon etiology*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection and infestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial, mycobacterial, or fungal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthropod bite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold panniculitis (popsicle panniculitis, equestrian panniculitis, subcutaneous fat necrosis of the newborn, sclerema neonatorum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factitial panniculitis (iatrogenic, accidental, or intentional injections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-irradiation panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Enzymatic destruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha-1 antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytophagic histiocytic panniculitis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia cutis/metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Deposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gouty panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calciphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperoxaluria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipodermatosclerosis (sclerosing panniculitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum migrans/subacute nodular migratory panniculitis/chronic erythema nodosum",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema induratum/nodular vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis (especially polyarteritis nodosa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial migratory thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-steroid panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panniculitis of dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue disease panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrobiosis lipoidica diabeticorum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous granuloma annulare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum leprosum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The list is not intended to be exhaustive.  Some conditions may be multifocal in etiology, eg, traumatic and inflammatory.  In some conditions, the etiology is not definitively established.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Cytophagic histiocytic panniculitis may not represent malignancy in all cases.",
"     <br/>",
"     &Delta; There is not consensus about whether subacute nodular migratory panniculitis is a variant of chronic erythema nodosum or a separate entity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1101=[""].join("\n");
var outline_f1_4_1101=null;
var title_f1_4_1102="IPF static deflation volume";
var content_f1_4_1102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship of the static deflation volume and pressure in a patient with idiopathic pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lung volume (as a percent of predicted TLC) is plotted against the static transpulmonary pressure (cmH2O) for a patient with ILD. In general, the compliance, maximum static transpulmonary pressure, and the coefficient of retraction (the maximum transpulmonary pressure to TLC) tend to correlate with the extent of parenchymal lung involvement observed on lung biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1102=[""].join("\n");
var outline_f1_4_1102=null;
var title_f1_4_1103="Etiology of dystonia a";
var content_f1_4_1103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70477%7EPEDS%2F51622%7EPEDS%2F63377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70477%7EPEDS%2F51622%7EPEDS%2F63377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       I. Primary dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. Sporadic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Inherited (all atosomal dominant)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Classic (Oppenheim's) dystonia (common in the Ashkenazi Jews, DYT1 - 9q34)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Childhood- and adult-onset cranial-cervical-limb dystonia (DYT6 - 8p21-22)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adult-onset cervical and other focal dystonia (DYT7 - 18p)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       II. Dystonia-plus syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. Sporadic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Progressive supranuclear palsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multiple system atrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cortico-basal ganglionic degeneration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Inherited",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Autosomal dominant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dopa-responsive dystonia (DRD) (DYT5-GTP cyclohydrolase I 14q22.1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dystonia-Myoclonus (alcohol responsive, chromosome - 18)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Autosomal recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Tyrosine hydroxylase deficiency (chromosome - 21)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Biopterin deficient diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Aromatic amino acid decarboxylase deficiency (dopamine-agonist responsive dystonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       III. Heredogenerative diseases (Typically not pure dystonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. X-linked recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lubag (X-linked dystonia-parkinsonism, DYT3 - Xq13)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pelizaeus-Merzbacher disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lesch-Nyhan syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Deafness, dystonia, retardation, blindness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Autosomal dominant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rapid-onset dystonia-parkinsonism (RDP)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Juvenile Parkinsonism-Dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Huntington disease (IT15 - 4p16.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spinocerebellar degenerations (SCA1- SCA8)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dentato-rubral-pallidoluysian atrophy (DRPLA) vary degeneration with Wernicke's encephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hereditary spastic paraplegia with dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thalamo-olivary degeneration with Wernicke's encephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       C. Autosomal recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Wilson disease (Cu-ATPase - 13q14.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neurodegeneration with brain iron accumulation type 1 (NBIA 1) (Hallervorden-Spatz disease - 20p12.3-p13)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ataxia telangiectasia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Heredogenerative diseases (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        D. Associated with metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Amino acid disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Glutaric acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Methylmalonic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Homocystinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hartnup's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tyrosinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Lipid disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Metachromatic leukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ceroid lipofuscinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Niemann-Pick type C (dystonic lipidosis, \"sea",
"blue\" histiocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gangliosidoses GM1-, GM2-variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hexosaminidase A",
"and B deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Other metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tyrosine hydroxylase deficiency (chromosome - 21)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Biopterin deficient diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Triosephosphate isomerase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Aromatic amino acid decarboxylase deficiency (dopamine-agonist",
"responsive dystonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Biotin-responsive basal ganglia disease [Ozand et",
"al, 1998]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        E. Unknown inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroacanthocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rett syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraneuronal inclusion disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infantile bilateral striatal necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial basal ganglia",
"calcifications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hereditary spastic paraplegia with dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deletion of",
"18q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        F. Mitochondrial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leigh disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leber disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        G. Due to a known specific cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perinatal cerebral injury and kernicterus: Athetoid cerebral palsy, delayed onset dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection: Viral encephalitis, encephalitis lethargica, Reye's syndrome; subacute sclerosing panencephalitis; Jakob-Creutzfeldt disease; HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other: Tuberculosis, syphilis, acute infectious torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs: Levodopa and dopamine agonists, dopamine receptor blocking drugs, fenfluramine, anticonvulsants, flecainide, ergots, certain calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxins: MN, CO, CS2, cyanide, methanol, disulfiram, 3-nitroproprionic acid, wasp sting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic: Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraneoplastic brainstem encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Heredogenerative diseases (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        G. Due to a known specific cause (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Cerebral vascular or ischemic injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central pontine myelinolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head trauma and brain surgery (thalamotomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peripheral trauma (with causalgia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrical injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        IV. Other hyperkinetic syndromes associated with dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A. Tic disorders with dystonic tics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        B. Paroxysmal dyskinesias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal kinesigenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal non-kinesigenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal exertion-induced",
"dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal hypnogenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"1\">",
"        C. Hypnogenic dystonia (probably a seizure disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        V. Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        VI. Pseudodystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atlanto-axial subluxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringomyelia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnold-Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trochlear nerve palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibular torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior fossa mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue neck mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital postural torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Congenital Klippel-Feil syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isaacs syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sandiffer's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Satoyoshi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiff-person syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventral hernia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_4_1103=[""].join("\n");
var outline_f1_4_1103=null;
